

CALGB Publications
Table 10
Group Bibliography, Published, 1/1/1995 - 5/31/2006

- 7521 A controlled trial of chemoimmunotherapy of acute myelogenous leukemia with the methanol extraction residue of tubercle bacilli (MER)
Cuttner J, Glidewell O, Holland JF
 In Immunotherapy of Human Cancer, Terry/Rosenberg (ed.) Elsevier North Holland, Inc., , 1999 *Published Date 8/20/1999*
- 7551 Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival—results of a Cancer and Leukemia Group B study
Coleman M, Rafla S, Propert KJ, Glicksman AS, Peterson BA, Nissen N, Brunner K, Holland JF, Anderson J, Gottlieb A, Kaufman T
 Int J Radiation Oncology Biol Phys 41(3):639-645, 1998 *Published Date 6/1/1998*
- 7581 The >20-year natural history of node-positive primary breast carcinoma treated with CMF-based adjuvant chemotherapy: A Study by the Cancer and Leukemia Group B
Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L
 Journal of Clinical Oncology 21(9):1825-1835, 2003 *Published Date 5/1/2003*
- 7581 The natural history of node-positive primary breast cancer treated with CMF-based adjuvant therapy
Weiss RB, Cirrincione CT, Demakos E, Holland JF, Falkson G, Robbins A, Bothun S, Berry DA, Henderson IC
 Anti-Cancer Drugs 6(2):87, 1995 *Published Date 1/1/1995*
- 7611 A comparative study of the long-term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation
Hill JM, Kornblith AB, Jones D, Freeman A, Holland JF, Glicksman AS, Boyett JM, Lenherr B, Brecher ML, Dubowy R, Kung F, Maurer H, Holland JC
 Cancer 82:208-218, 1998 *Published Date 2/1/1998*
- 7951 Single agent versus combination chemotherapy in follicular, low grade lymphomas. A study of the Cancer and Leukemia Group B
Peterson BA, Petroni GR, Frizzera G, Barcos MP, Bloomfield CD, Nissen N, Hurd DD, Henderson E, Sartiano GP, Johnson JL, Holland JF, Gottlieb A
 Journal of Clinical Oncology 21(1):5-15, 2003 *Published Date 1/1/2003*
- 7951 Second malignancies in patients with follicular, low grade lymphomas. An analysis of CALGB 7951
Petroni GR, Johnson JL, Barcos M, Peterson BA
 Proc ASCO 15: 418, 1996 *Published Date 1/1/1996*
- 8082 Association of Angiogenesis in Lymph Node Metastases with Outcome of Breast Cancer
Guidi AJ, Berry DA, Broadwater GJ, Perloff M, Norton L, Barcos MP, Hayes DF
 J Natl Cancer Inst 92 (6):486-492, 2000 *Published Date 3/15/2000*
- 8082 Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a noncross-resistant regimen: a CALGB study
Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb AJ, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Holland JF
 J Clin Oncol,14 (5):1589-1598, 1996 *Published Date 1/1/1996*
- 8082 Psychological symptoms and disease-free and overall survival in women with stage II breast cancer: a Cancer and Leukemia Group B study
Tross S, Herndon J, Korzun A, Kornblith AB, Cella D, Holland JF, Raich P, Johnson A, Kiang DT, Perloff M, Norton L, Wood W, Holland JC
 J Natl Cancer Inst 88:661-667, 1996 *Published Date 1/1/1996*

- 8083 Thoracic radiation therapy added to chemotherapy for small cell lung cancer: An update of Cancer and Leukemia Group B study 8083
Perry MC, Herndon JE, Eaton WL, Green MR
 Journal of Clinical Oncology 16(7):2466-2467, 1998 *Published Date 7/10/1998*
- 8083 Thoracic radiation therapy added to chemotherapy for small cell lung cancer: An update of Cancer and Leukemia Group B study 8083
Perry, Herndon JE, Eaton W, Green MR
 Proc ASCO 15:384, 1996 *Published Date 1/1/1996*
- 8281 Combination chemotherapy for metastatic or recurrent carcinoma of the breast—A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: CALGB # 8281
Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, Wood W, Henderson IC
 J Clin Oncol 13(6): 1443-1452, 1995 *Published Date 1/1/1995*
- 8361 High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection - Cancer and Leukemia Group B Study 8361
Baer MR, Stewart CC, Dodge RK, Leget GA, Schiffer CA, Powell BL, Kolitz JE, Davey F, Carroll AJ, Bloomfield CD
 Blood 97:3574-3580, 2001 *Published Date 6/1/2001*
- 8361 Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia: FAB-M6): a CALGB study
Davey FR, Abraham N, Brunetto VL, Maccallum JM, Nelson DA, Ball ED, Griffin JD, Baer MR, Wurster-Hill D, Mayer RJ, Schiffer CA, Bloomfield CD
 Am J Hematol 49:29-38, 1995 *Published Date 1/1/1995*
- 8361 High frequency of change in immunophenotype of acute myeloid leukemia at first relapse demonstrated by multiparameter flow cytometry
Baer MR, Stewart CC, Yosucio V, Lawrence D, Arthur D, Bloomfield CD
 Blood 86 (10): 332a, 1995 *Published Date 1/1/1995*
- 8361 Multiparameter flow cytometry (MFC) analysis of de novo acute myeloid leukemia (AML) reveals low frequencies of lymphoid antigen expressions and strong associations between immunophenotype and karyotype
Baer MR, Stewart CC, Lawrence D, Powell B, Schiffer CA, Davey FR, Arthur DC, Bloomfield CD
 Blood 86 (10): 266a, 1995 *Published Date 1/1/1995*
- 8364 Value of immunophenotype (IP) in intensively treated adult acute lymphoblastic leukemia (ALL): CALGB 8364
Frankel SR, Stewart CC, Dodge R, Davey F, Larson RA, Sztatrowski TP, Schiffer CA, Bloomfield CD
 Blood 86 (10): 173a, 1995 *Published Date 1/1/1995*
- 8433 Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
Dillman RO, Herndon JE, Seagren SL, Eaton WL, Green MR
 J Natl Cancer Inst 88 (17):1210-1215,1996 *Published Date 1/1/1996*

- 8461 Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): results from Cancer and Leukemia Group B study 8461
Marcucci G, Mrozek KA, Ruppert AS, Maharry KS, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD
Journal of Clinical Oncology 23(24):5705-5717, 2005 *Published Date 8/20/2005*
- 8461 Comparison of pretreatment characteristics and outcome of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations involving 11q23
Blum WG, Mrozek KA, Maharry KS, Raimondi SC, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD
Proc ASCO:6549, 2005 *Published Date 5/16/2005*
- 8461 Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: CALGB 8461
Farag SS, Ruppert AS, Mrozek KA, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru P, Stamberg J, Baer MR, Block AM, Vardiman JW, Kolitz JE, Larson RA
Journal of Clinical Oncology 23(3):482-493, 2005 *Published Date 1/20/2005*
- 8461 Early allogeneic transplantation should be considered for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461 and review of the literature
Blum WG, Mrozek KA, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD
Cancer 101:1420-1427, 2004 *Published Date 12/25/2004*
- 8461 t(8;21) acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome and prognostic factors predicting outcome: a Cancer and Leukemia Group B study
Marcucci G, Mrozek KA, Ruppert AS, Maharry KS, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD
Blood 104(11):2017, 2004 *Published Date 12/1/2004*
- 8461 Central review of cytogenetics is essential for cooperative group clinical and correlative studies of acute leukemia: the Cancer and Leukemia Group B (CALGB) 8461 experience
Mrozek KA, Carroll AJ, Maharry KS, Rao KW, Patil SR, Pettenati MJ, Watson MS, Arthur DC, Tantravahi R, Heerema NA, Koduru P, Bigner SH, Stamberg J, Block AM, Edwards CG, Sterling LJ, Bloomfield CD
Blood 104(11):1081, 2004 *Published Date 12/1/2004*
- 8461 Acute myeloid leukemia (AML) with t(6;9)(p23;q24) defines a very poor risk subtype Of leukemia with distinguishing clinical-pathological features: a US cytogenetics intergroup study of 62 t(6;9) AML cases
Slovak M, Bloomfield CD, Gundacker H, Alonzo T, Dewald G, Appelbaum F, Ravindranath Y, Tallman M, Larson RA, Carroll AJ, Hirsch BA, Raimondi S, Heerema NA
Blood 104(11):567, 2004 *Published Date 12/1/2004*
- 8461 Pre-treatment cytogenetics predict complete remission and long-term outcome in patients over 60 years with acute myeloid leukemia: results from CALGB 8461
Farag SS, Archer KJ, Mrozek KA, Vardiman JW, Carroll AJ, Pettenati MJ, Powell BL, Moore JO, Kolitz JE, Baer MR, Bigner SH, Koduru P, Stamberg J, Mayer RJ, Stone RM, Schiffer CA, Larson RA, Bloomfield CD
Blood 104(11):568, 2004 *Published Date 12/1/2004*
- 8461 Core binding factor in adult acute myeloid leukemia (AML)
Bloomfield CD, Ruppert AS, Mrozek KA, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA
Annals of Hematology 83:S84-85, 2004 *Published Date 7/4/2004*
- 8461 Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461
Marcucci G, Mrozek KA, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru P, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD
Journal of Clinical Oncology 22(12):2410-2418, 2004 *Published Date 6/15/2004*
- 8461 Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461
Marcucci G, Mrozek KA, Ruppert AS, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PR, Anastasi J, Larson RA, Bloomfield CD
Proc ASCO:6514, 2004 *Published Date 5/1/2004*
- 8461 Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461
Bloomfield CD, Blum WG, Carroll AJ, Larson RA, Mrozek KA, Pettenati MJ, Rao KW, Ruppert AS, Vardiman JW
Proc ASCO:6543, 2004 *Published Date 5/1/2004*

- 8461 Repetitive cycles of high-dose cytarabine may decrease cumulative incidence of relapse in patients with inv(16)(p13q22) or t(16;16)(p13;q22): results from Cancer and Leukemia Group B (8461)
Byrd JC, Ruppert AS, Mrozek KA, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru P, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD
Journal of Clinical Oncology 22(6):1087-1094, 2004 *Published Date 3/15/2004*
- 8461 Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML)
Bloomfield CD, Byrd JC, Farag SS, Mrozek K, Dodge RK, Archer KJ, Whitman S, Larson RA, Carroll AJ, Caligiuri MA
Annals of Hematology 80 (Suppl II):S10 (#37), 2001 *Published Date 11/1/2001*
- 8461 Secondary Chromosome Aberrations in Adult Acute Lymphoblastic Leukemia (ALL) with t(9;22)
Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Vardiman JW, Larson RA, Bloomfield CD
Blood 98 (Suppl 1):466, 2001 *Published Date 11/1/2001*
- 8461 Abnormal Karyotype during Complete Remission Predicts Short Relapse-Free Survival (RFS) in Acute Myeloid Leukemia (AML)
Marcucci G, Archer KJ, Mrozek K, Carroll AJ, Sterling LJ, Edwards CG, Larson RA, Bloomfield CD
Blood 98 (Suppl 1):2421, 2001 *Published Date 11/1/2001*
- 8461 Pre-Treatment Cytogenetics Predict Initial Induction Success and Overall Survival in Adult Patients with De Novo Acute Myeloid Leukemia
Byrd JC, Mrozek K, Dodge R, Carroll AJ, Edwards C, Pettenati MJ, Patil SR, Larson RA, Bloomfield CD
Blood 98 (Suppl 1):1912, 2001 *Published Date 11/1/2001*
- 8461 Trisomy 8 as an isolated cytogenetic abnormality is an adverse prognostic factor in patients with acute myeloid leukemia (AML) - results from CALGB 8461
Farag SS, Archer KJ, Carroll AJ, Pettenati MJ, Mayer RJ, Stone RM, Larson RA, Bloomfield CD
Proc ASCO 20:282a (#1124), 2001 *Published Date 5/1/2001*
- 8461 Karyotype change in adult acute myeloid leukemia (AML) at first relapse
Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Larson RA, Bloomfield CD
Blood 96 (Suppl 1):706a (#3046), 2000 *Published Date 4/1/2000*
- 8461 Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
Byrd JC, Dodge RK, Carroll AJ, Baer MR, Edwards CG, Stamberg J, Qumsiyeh MB, Moore JO, Mayer RJ, Larson RA, Bloomfield CD
Journal of Clinical Oncology 17(12):3767-3775, 1999 *Published Date 12/15/1999*
- 8461 Adult AML patients with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered
Bloomfield CD
Annals of Hematology 78 (suppl II):S13, 1999 *Published Date 11/11/1999*
- 8461 Adult acute myeloid leukemia (AML) patients (pts) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered
Byrd JC, Dodge RK, Carroll AJ, Baer MR, Edwards CG, Stamberg J, Qumsiyeh MB, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD
Blood 92(10) Suppl:#1282, 1998 *Published Date 11/15/1998*
- 8461 Trisomy 8 represents a poor risk group in adult acute lymphoblastic leukemia (ALL)—Results from CALGB 8461
Wetzler M, Dodge RK, Mrozek KA, Carroll AJ, Larson RA, Bloomfield CD
Blood 91 (Suppl 1):223a #914, 1998 *Published Date 11/15/1998*
- 8461 t(9;11) (p22;q23) confers better prognosis than other translocations of 11q23 in adults with de novo acute myeloid leukemia (AML)
Mrozek KA, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Schiffer CA, Bloomfield CD
Cytogenet Cell Genet. 77:136, 1997 *Published Date 6/22/1997*
- 8461 Isochromosome 12p in two cases of acute myeloid leukemia without evidence of germ cell tumor
KH, PNR, JLS, JC, CDB, KM
Br J Haematol 93:677-680, 1996 *Published Date 1/1/1996*
- 8461 Acute myeloid leukemia (AML) patients with pre-treatment isolated trisomy 8 are a poor prognostic group who are rarely cured with chemotherapy: results of CALGB 8461
Byrd JC, Lawrence D, Arthur DC, Davey F, Schiffer CA, Bloomfield CD
Proc Am Assoc Cancer Res 37:188, 1996 *Published Date 1/1/1996*

- 8461 Rearrangement of ALL1 in adult acute myeloid leukemia (AML) with normal cytogenetics is a recurrent molecular defect that predicts a short complete remission (CR) duration.
Caligiuri MA, Strout MP, Arthur DC, Baer MR, Shah D, Block AW, Mrozek K, Yu F, Oberkircher A, Lawrence D, Knuutila S, Ruuru T, Herzog GP, Schiffer CA, Bloomfield CD
Proc ASCO 15:360, 1996 *Published Date 1/1/1996*
- 8461 Secondary cytogenetic changes in acute promyelocytic leukemia (APL): prognostic importance and association with the intron 3 breakpoint of the promyelocytic leukemia (PML) gene
Slack JL, Arthur DC, Lawrence D, Moshier A, Mrozek K, Tantravahi R, Pettenati M, Bigner S, Davey FR, Mayer RJ, Moore JO, Schiffer CA, Bloomfield CD
Proc Am Assoc Cancer Res 37:557, 1996 *Published Date 1/1/1996*
- 8461 Trisomy 11 as the sole karyotypic abnormality identifies a group of older patients with acute myeloid leukemia (AML) with FAB M2 or M1 and unfavorable clinical outcome: results of CALGB 8461
Heinonen K, Mrozek K, Lawrence D, Arthur D, Davey F, Pettenati M, Bigner S, Moore J, Mayer R, Schiffer CA, Bloomfield CD
Proc Am Assoc Cancer Res 37:186, 1996 *Published Date 1/1/1996*
- 8461 Der(16)t(1;16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia chromosome-positive acute lymphoblastic leukemia
Mrozek K, Arthur DC, Karakousis CP, Koduru PRK, LeBeau MM, Pettanati MJ, Tantravahi R, Mrozek E, Perez-Mesa C, Rao UNM, Frankel SR, Davey FR, Bloomfield CD
Int J Oncol 6:531-538, 1995 *Published Date 1/1/1995*
- 8461 Extramedullary leukemia (EML) is associated with pre-treatment cytogenetic abnormalities in patients with acute myeloid leukemia (AML)
Byrd JC, Edenfield WJ, Arthur DC, Lawrence D, Shah D, Trikha E, Weiss RB, Schiffer CA, Bloomfield CD
Blood 86 (10):43a, 1995 *Published Date 1/1/1995*
- 8461 Power calculations for mixture models in survival
Lawrence DD, Priore RL, George SL
Proc International Biometric Society:99, 1995 *Published Date 1/1/1995*
- 8461 The partial tandem duplication of ALL1 as a recurrent novel molecular defect in acute myeloid leukemia (AML) with trisomy 11
Strout MP, Caligiuri MA, Schichman SA, Mrozek K, Herzog GP, Arthur DC, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Croce CM, Bloomfield CD
Blood 86 (10):429a, 1995 *Published Date 1/1/1995*
- 8525 Patients with acute myeloid leukemia (AML) and mutant RAS proto-oncogenes benefit from intensification with high-dose cytarabine (HDAC): results from the randomized Cancer and Leukemia Group B (CALGB) 8525 study
Neubauer A, Mahary KS, Marcucci G, Mrozek KA, Mayer RJ, Larson RA, Liu ET, Bloomfield CD
Proc ASCO:6514, 2005 *Published Date 5/16/2005*
- 8525 Intensified post-remission chemotherapy for adults with AML: an update of CALGB 8525
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Shulman P, Omura GA, Moore GO, McIntyre OR, Frei III E
Leukemia Symposium, 1995 *Accepted Date 1/1/1995*
- 8534 Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited stage small cell lung cancer: CALGB protocol 8534: A Cancer and Leukemia Group B Study
Maurer LH, Herndon JE, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR
Journal of Clinical Oncology 15(11):3378-3387, 1999 *Published Date 11/1/1999*
- 8534 Psychological and neuropsychological functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, for Cancer and Leukemia Group B, study 8534
Ahles TA, Silberfarb P, Herndon JE, Maurer LH, Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski LL, Green MR, Holland JC
Journal of Clinical Oncology 16(5):1954-1960, 1998 *Published Date 5/1/1998*

- 8541 A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
Dressler LG, Broadwater G, Berry DA, Cirrincione CT, Cowan D, Harris LN, Moore D, Muss HB, Hayes DF, Ellis MJ
Proc ASCO:566, 2004 *Published Date 5/1/2004*
- 8541 Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CC, Muss HB, Green MR, Norton L, Frei E
J Natl Cancer Inst 90(16):1205-1211, 1998 *Published Date 8/19/1998*
- 8541 Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541
Roach MR, Cirrincione CT, Budman DR, Hayes DF, Berry DA, Younger J, Hart R, Henderson IC
Cancer J Sci Am 1997:107-112, 1997 *Published Date 4/18/1997*
- 8541 The relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer (CALGB 8541)
Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL
J Clin Oncol 14(11): 3000-3008,1996 *Published Date 1/1/1996*
- 8541 The relationship between toxicity and obesity in adjuvant therapy for breast cancer (CALGB 8541)
Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL
Proc ASCO 14: 111, 1995 *Published Date 1/1/1995*
- 8542 Alternating Chemotherapy Regimens for Patients With Metastatic Breast Cancer--A Pilot Study Based on Tumor Marker Kinetics
Kiang DT, Kennedy BJ, Younger J, Perry MC, Schilling A, Faraggi D, Korzun AH, Nowak B, Wood W
Cancer 75 (3):826-830, 1995 *Published Date 2/1/1995*
- 8581 Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B
Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, Ozer H, Golomb H, Bloomfield CD
Leukemia 9(7):1116-1120, 1995 *Published Date 1/1/1995*
- 8631 A Phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: A Cancer and Leukemia Group B study
Mitchell EP, Perry MC, Luikart SD, Cirrincione CT, Echo DV, Herndon JF, Maurer LH, Clamon G, Green MR
Lung Cancer, 15 (2): 215-223,1996 *Published Date 1/1/1996*
- 8634 Induction chemoradiation followed by surgery in stage IIA non-small cell carcinoma of the lung (NSCLC): long term results of Cancer and Leukemia Group B protocol 8634
Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Green MR
Proc ASCO 15: 376, 1996 *Published Date 1/1/1996*
- 8642 Safety and Efficacy of Using a Single Agent Or a phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study: CALGB 8642
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione CT, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL
Journal of Clinical Oncology 17(5):1397-1406, 1999 *Published Date 5/1/1999*
- 8642 Amonafide: an active agent in the treatment of previously untreated advanced breast cancer: a Cancer and Leukemia Group B Study (CALGB 8642)
Costanza ME, Berry DA, Henderson IC, Ratain MJ, Wu KP, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss A
Clinical Cancer Research 1(7):699-704, 1995 Clin Can Res 1:699-704, 1995 *Published Date 1/1/1995*
- 8642 A randomized comparison of single agent induction chemotherapy vs. standard chemotherapy for stage IV breast cancer: CALGB 8642
Costanza ME, Henderson IC, Berry D, Cirrincione C, Frei E, McIntyre OR, Weiss RB
Proc ASCO 14: 116, 1995 *Published Date 1/1/1995*

- 8661 Risk of adult leukemia in relation to prior immune-related conditions
Cooper GS, Kamel, Sandler DP, Davey FR, Bloomfield CD
Ca Epid, Biomarkers & Prev 5:867-872, 1996 *Published Date 11/1/1996*
- 8661 Carcinogen metabolism polymorphism and myelodysplastic syndrome
Chen H, Sandler D, Taylor JA, Watson M, Shore DL, Liu E, Bell DA
Proc Am Assoc Ca Res 36:133, 1995 *Published Date 1/1/1995*
- 8661 Exposure to chemicals and risk for myelodysplastic syndrome (MDS)
Sandler DP, Shore DL, Liu E, Bloomfield CD
Am J Epidemiol S60:141, 1995 *Published Date 1/1/1995*
- 8662 Circulating HER2/c-neu extra cellular domain (ECD/HER2) as a prognostic factor in patients with metastatic breast cancer: a Cancer and Leukemia Group B study
Hayes DF, Yamauchi H, Broadwater GJ, Cirrincione CT, Carney W, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC
Clinical Cancer Research 7:2703-2711, 2001 *Published Date 9/5/2001*
- 8691 A Prognostic Model for Low-Grade Follicular Non-Hodgkin's Lymphoma
Seng JE, Petroni GR, Oken MM, Barcos MP, Peterson BA
Proc ASCO 17:10a-35, 1998 *Published Date 5/15/1998*
- 8691 Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486)
Peterson BA, Petroni GR, Oken MM, Johnson JL, Barcos MP, Cooper MR
Proc ASCO 16:14a, 1997 *Published Date 5/1/1997*
- 8693 Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis. An Intergroup Study
Mansour EG, Gray R, Shatila AH, Tourmey DC, Cooper MR, Osborne CK, Falkson G
Journal of Clinical Oncology 16 (11):3486-3492, 1998 *Published Date 11/1/1998*
- 8695 MOPP/ABV Hybrid Chemotherapy for Advanced Hodgkin's Disease Significantly Improves Failure-Free and Overall Survival: The 8-Year Results of the Intergroup Trial
Glick JH, Young ML, Harrington DP, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM
Journal of Clinical Oncology 16(1):19-26, 1998 *Published Date 1/15/1998*
- 8722 An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by the Cancer and Leukemia Group B
Lee EJ, George SL, Amrein PC, Paciucci PA, Allen SL, Schiffer CA
Leukemia 12(3):139-143, 1998 *Published Date 2/1/1998*

- 8733 A phase II study of recombinant interferon-gamma as maintenance therapy following combination chemotherapy for patients with extensive small cell lung cancer
Bitran J, Green M, Perry M, Hollis DR, Herndon JE
Am J Clin Oncol 18(1): 67-70, 1995 *Published Date 1/1/1995*
- 8741 Dose Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741
Abrams J, Aisner J, Cirrincione CT, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci LL, Kirshner J, Ellerton J, Norton L
Journal of Clinical Oncology 17(1):64-73, 1999 *Published Date 1/10/1999*
- 8751 EVA (Etoposide, Vinblastine, Doxorubicin): an active regimen for the treatment of Hodgkin's disease in relapse following MOPP
Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA
J Clin Oncol 13(8): 2005-2011, 1995 *Published Date 1/1/1995*
- 8752 Prevalence of HTLV-I associated T-Cell Lymphoma
Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan DB, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai KR, Sawitsky A, Sheremata L, Dosik H, Cunningham C, Montagna R
American Journal of Hematology 66:32-38, 2001 *Published Date 1/3/2001*
- 8761 Blood molecular analysis is highly correlated to bone marrow cytogenetics as a biologic endpoint in chronic myelogenous leukemia (cml): CALGB 8761
Stock W, Westbrook CA, Peterson B, Szatrowski TP, Silver RT, Arthur DC, Schiffer CA, Bloomfield CD
Proc ASCO 14: 429, 1995 *Published Date 1/1/1995*
- 8762 Quantitative molecular monitoring of BCR/ABL transcripts in adult acute lymphoblastic leukemia (ALL) using a real-time PCR assay: pilot study from the Cancer and Leukemia Group B (CALGB 8762)
Stock W, Sher D, Dodge RK, Caligiuri M, Frankel S, Larson RA, Bloomfield CD
Blood 93(suppl 1):287a (#1281), 1999 *Published Date 10/31/1999*
- 8762 PCR monitoring of minimal residual disease identifies good outcome in bcr/abl positive acute lymphoblastic leukemia (ALL): CALGB 8762
Westbrook CA, Dodge R, Szatrowski TP, Horrigan SK, Kim SJ, Wu D, Jantzen N, Schiffer CA, Bloomfield CD
Blood 88 (10):477a, 1996 *Published Date 1/1/1996*
- 8762 Low incidence of TAL1 gene rearrangements in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762)
Stock W, Westbrook CA, Sher DA, Dodge R, Sobol RE, Wurster-Hill D, Davey FR, Larson RA, LeBeau MM, Aplan PD, Frankel SR, Stewart CC, Bloomfield CD
Clin Can Res 1:459-463, 1995 *Published Date 1/1/1995*
- 8762 High incidence of p16 deletion in adult acute lymphoblastic leukemia (ALL): Correlation with clinical features and response to treatment: CALGB 8762
Stock W, Shar DA, Dodge RK, Westbrook CA, Larson RA, Arthur D, Frankel SR, Sobol RE, Davey FR, Schneider D, Diaz MO, Bloomfield CD
Blood 86 (10): 268a, 1995 *Published Date 1/1/1995*

- 8782 Five year follow-up of high dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving > 10 axillary lymph nodes (Duke/CALGB 8782)
Peters WP, Berry D, Vredenburg JJ, Hussein A, Rubin P, Elkordy M, Ross M, Henderson IC, Budman D, Norton L, Weiss R, Hurd D
Proc ASCO 14:317, 1995 *Published Date 1/1/1995*
- 8791 Randomized comparison of pentostatin versus interferon alpha-2a in previously untreated patients with hairy cell leukemia: an intergroup study
Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth P, Habermann T, Golomb HM, Rai KR, Eisenhauer E, Appelbaum F, Cheson BD
Journal of Clinical Oncology 13:974-982, 1995 *Published Date 1/1/1995*
- 8811 Hypersensitivity reactions to L-Asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia
Larson RA, Fretzin MH, Dodge RK, Schiffer CA
Leukemia 12(5):660-665, 1998 *Published Date 5/1/1998*
- 8832 Phase I trial of Etoposide, Carboplatin, and GM-CSF in Extensive Small-Cell Lung Cancer. A Cancer and Leukemia Group B study (CALGB 8832)
Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR
Am J Clin Oncol 20 (1):24-30, 1997 *Published Date 2/1/1997*
- 8833 Dihydro-5 Azacytadine in Malignant Mesothelioma: A Phase II Trial Demonstrating Activity by Cardiac Toxicity
Vogelzang NJ, Herndon JE, Cirrincione CT, Harmon D, Antman K, Corson JJ, Suzuki Y, Citron ML, Rai KR, Green MR
Cancer 79 (11):2237-2242, 1997 *Published Date 11/1/1997*
- 8835 Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer, a phase II trial
Clamon G, Herndon JE, Akerley W, Green M
Lung Cancer 19:25-29, 1998 *Published Date 2/28/1998*
- 8837 Long term survival data from CALGB 8837: Radiation dose escalation and concurrent chemotherapy (CT) in Limited Stage Small Cell Lung Cancer (LD-SCLC). Possible dose-survival relationship for total radiation dose and dose intensity
Choi NC, Herndon JE, Rosenman J, Carey R, Chung CT, Bogart J, Seagren S, Green MR
Proc ASCO 21:1190, 2002 *Published Date 5/2/2002*
- 8837 Phase I study to determine the maximum tolerated dose (MTD) of radiation in standard daily and hyperfractionated-accelerated twice daily radiation schedules with concurrent chemotherapy for limited stage small cell lung cancer (Cancer and Leukemia Group B 8837)
Choi NC, Herndon JE, Rosenman J, Carey RW, Chung C, Bernard S, Leone LA, Seagren SL, Green MR
Journal of Clinical Oncology 16(11):3528-3537, 1998 *Published Date 11/1/1998*
- 8837 Phase I study to determine the maximum tolerated dose (mtd) of radiation in standard daily (qd) and accelerated twice daily (bid) radiation schedules with concurrent chemotherapy (ct) for limited stage small cell lung cancer: CALGB 8837
Choi NC, Herndon J, Rosenman J, Carey R, Chung CT, Bernard S, Leone L, Seagren S, Green M
Proc ASCO 14: 363, 1995 *Published Date 1/1/1995*

- 8856 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide (CHOPE) for advanced stage Hodgkin's Disease: CALGB 8856
Lester EP, Petroni GR, Barcos MP, Johnson JL, Millard F, Cooper MR, Omura GA, III EF, Peterson BA
Cancer Investigation 19(5):447-458, 2001 *Published Date 7/16/2001*
- 8856 CALGB 8856: a phase II study of CHOPE (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) for advanced stage Hodgkin's disease: an analysis of cohort II
Lester EP, Petroni GR, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, Peterson BA
Proc ASCO 15: 416, 1996 *Published Date 1/1/1996*
- 8856 CHOPE (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) for advanced stage Hodgkin's disease (HD), a Phase II study: CALGB 8856
Lester EP, Petroni GR, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, Peterson BA
VI International Conference on Malignant Lymphoma Lugana, 1996 *Published Date 1/1/1996*
- 8856 CHOPE [cyclophosphamide (c), doxorubicin (h), vincristine (o), prednisone (p) and etoposide (e)] followed by ABVD for advanced stage Hodgkin disease (HD), a phase II study: CALGB 8856
Lester EP, Petroni GR, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, Peterson BA
Proc ASCO 14: 391, 1995 *Published Date 1/1/1995*
- 8861 Association of angiogenesis in lymph node metastases with outcome of breast cancer
Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF
Journal of the National Cancer Institute 92(6):486-492, 2000
Journal of the National Cancer Institute 92(6):486-492, 2000
Published Date 3/15/2000
- 8862 Population pharmacodynamic study of amonafide: Cancer and Leukemia Group B 8862
Ratain MJ, Rosner G, Allen S, Van Echo D, Costanza M, Henderson IC, Schilsky R
J Clin Oncol 13(3):741-747, 1995 *Published Date 1/1/1995*
- 8869 Flow cytometry analysis in node positive breast cancer with emphasis on standardization and clinical outcome: A companion trial of the Cancer and Leukemia Group B.
Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Barcos M, Thor A, Koerner F, Henderson IC
Communications in Clinical Cytometry, 22: 297-306, 1995 *Published Date 1/1/1995*
- 8882 Autologous bone marrow transplantation (ABMT) in acute myeloid leukemia (AML) at relapse using monoclonal antibody-purged bone marrow: CALGB study 8882
Mills LE, Ball ED, Rybka W, Hurd DD, Gingrich R, Rosner GL, Schiffer C
Blood 86 (Suppl): 959a, 1995 *Published Date 1/1/1995*
- 8894 Radiation Therapy Quality Control in a Clinical Trial of Adjuvant Postoperative Treatment for Rectal Cancer
Martenson JA, Urias R, Smolley SR, Coia LR, Tepper JE, Rotman M, Rich TA, O'Connell MJ
Int J Radiation Oncology Biol Phys 32(1): 51-55, 1995 *Published Date 1/1/1995*

- 8896 Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes: Intergroup 0089
Berger AC, Sigurdson E, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller D
Journal of Clinical Oncology 23(34):8706-8712, 2005 *Published Date 12/1/2005*
- 8896 Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ
Journal of Clinical Oncology 23(34):8671-8678, 2005 *Published Date 12/1/2005*
- 8896 Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer
McCullum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS
J Natl Cancer Inst 94 (15):1160-1167, 2002 *Published Date 8/7/2002*
- 8896 Surveillance for Second Primary Colorectal Cancer after Adjuvant Chemotherapy: An Analysis of Intergroup 0089
Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG
Annals of Internal Medicine 136 No. 4:261-269, 2002 *Published Date 2/19/2002*
- 8896 Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five- year final report of INT-0089
Haller DG, Catalano PJ, MacDonald J, Mayer RJ
Proc ASCO 17:256a-982, 1998 *Published Date 5/15/1998*
- 8896 Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four- year results of INT- 0089
Haller DG, Catalano PJ, MacDonald J, Mayer RJ
Proc ASCO 16:265a, 1997 *Published Date 5/1/1997*
- 8896 Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
O'Connell MJ, Mailliard JA, Kahn MJ, MacDonald JS, Haller DG, Mayer RJ, Wieand HS
J Clin Oncol 15(1):246-250, 1997 *Published Date 1/15/1997*
- 8896 Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089
Haller DG, Catalano PJ, MacDonald JS, Mayer R
Proc ASCO 15:211,1996 *Published Date 1/1/1996*
- 8896 Gender as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer
Haller DG, Catalano P, Macdonald JS, Mayer RJ, Hodi FS
 Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, 1995
 Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, 1995
Published Date 1/1/1995
- 8897 Randomized, controlled trail of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluououracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102
Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin S, Osborne CK
Journal of Clinical Oncology 23 (33):8313-8321, 2005 *Published Date 11/20/2005*
- 8897 CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results
Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K
 22nd Annual San Antonio Breast Cancer Symposium:#1, 1999 *Published Date 5/1/1999*
- 8897 CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102.
Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson IC, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K
 Proc ASCO 17:1a #2, 1998 *Published Date 4/1/1998*
- 8897 Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.
Albain KS, Green SR, Lichter AS, Hutchins LF, Wood WC, Henderson IC, Ingle JN, O'Sullivan J, Osborne CK, Martino S
J Clin Oncol 14 (11):3009-3017, 1996 *Published Date 11/1/1996*

- 8921 Subcutaneous azacytidine compared to supportive care in Patients with myelodysplastic syndrome: A Cancer and Leukemia Group B study
Silverman LR, Demakos EP, Peterson BL, Odchimar-Reissig R, Nelson D, Kornblith AB, Stone R, Holland JC, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JF
Cancer Invest 17(suppl 1):4 (#5), 1999 *Published Date 4/1/1999*
- 8923 Post-remission therapy in older patients with de novo acute myeloid leukemia (AML): A randomized trial of mitoxantrone/intermediate dose cytarabine 'versus' standard dose cytarabine (CALGB study 8923)
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Bloomfield CD, Schiffer CA
Blood 98:548-553, 2001 *Published Date 8/1/2001*
- 8923 Post-remission therapy in older patients with de novo acute myeloid leukemia (AML): A randomized trial of mitoxantrone/intermediate dose cytarabine 'V' standard dose cytarabine (CALGB 8923)
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Schiffer CA
Blood 90(10) Suppl:506a-2255, 1997 *Published Date 11/15/1997*
- 8923 Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA
New England Journal of Medicine 332(25):1671-1677, 1995 *Published Date 6/22/1995*
- 8931 Is Quality of Life Predictive of Survival Among Patients with Advanced Non-Small Cell Lung Carcinoma?
Herndon JE, Fleishman S, Kornblith AB, Kosty MP, Green MR, Holland JC
Cancer 85(2):333-340, 1999 *Published Date 1/15/1999*
- 8931 A longitudinal study of quality of life in advanced non-small cell lung cancer: CALGB 8931
Herndon JE, Fleishman S, Kosty MP, Green MR
Control Clin Trials 18:286-300, 1997 *Published Date 11/1/1997*
- 8931 A randomized trial of hydrazine sulfate in advanced non-small cell lung cancer: CALGB 8931
Herndon JE II, Fleishman S, Kosty M, Green M
American Statistical Association, 1-9, 1995 *Published Date 1/1/1995*
- 8932 Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study
Muscato JJ, Cirrincione C, Clamon G, Perry MC, Omura G, Berkowitz I, Reid T, Herndon JE, Green MR
Lung Cancer: 13, 285-294,1995 *Published Date 1/1/1995*
- 8935 Long term survival outcome of a sequential trimodality trial in pathologically staged IIIA(N2) Non-Small Cell Lung Cancer (NSCLC): Final results of Cancer and Leukemia Group B Protocol 8935.
Kumar P, Herndon JE, Sugarbaker DJ, Kohman LJ, Elias AD, Green MR
Proc ASCO 19:496a-1939, 2000 *Published Date 5/20/2000*
- 8935 N2 status at resection predicts long-term outcome following induction therapy for stage IIIA non-small cell lung cancer: CALGB 8935
Sugarbaker DJ, Herndon JE, DeCamp MM, Jaklitsch MT, Richards W, Kumar P, Green MR
Proc ASCO 17:452a-1739, 1998 *Published Date 5/15/1998*
- 8935 Patterns of disease failure following tri-modality therapy in pathologically staged IIA (N2) non-small cell lung cancer: analysis of Cancer and Leukemia Group B protocol 8935
Kumar P, Herndon J, Langer M, Kohman LJ, Shennib H, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ
Cancer 77(11):2393-2399, 1996Cancer, 77 (11): 2393-2399, 1996 *Published Date 1/1/1996*
- 8935 Results of Cancer and Leukemia Group B Protocol 8935: A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer
Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR, and the Cancer and Leukemia Group B Thoracic Surgery Group
J Thorac and Cardiovasc Surg 109(3):473-485, 1995 *Published Date 1/1/1995*

- 8935 Patterns of relapse following tri-modality treatment in patients with pathologically staged IIIA (N2) non-small cell lung cancer (NSCLC): analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935
Kumar P, Herndon J, Langer M, Liptay MJ, Sugarbaker DJ, Kohman LJ, Shennib H, Elias AD, Eaton WL, Kass FC, Seagren SL, Green MR
Proc American Radium Society, p. 31, 1995 *Published Date 1/1/1995*
- 8945 High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B (CALGB)
Breast Cancer Research and Treatment 36: 35-40, *Published Date 1/1/1995*
- 8952 A randomized comparison of ABVD vs MOPP/ABV for the treatment of advanced Hodgkin's Disease: Report of an Intergroup Trial
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Peterson BA
Journal of Clinical Oncology 21(4):607-614, 2003 *Published Date 2/15/2003*
- 8952 MOPP/ABV vs ABVD for advanced Hodgkin's disease: A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC)
Duggan DB, Petroni GR, Johnson JL, Hanson K, Glick JH, Connors JM, Cherny RC, Barcos MP, Peterson BA
Proc ASCO 16:12a, 1997 *Published Date 5/1/1997*
- 8963 Long-term psychosocial adaptation of survivors of acute leukemia: a Cancer and Leukemia Group B quality of life study
Greenberg DB, Herndon JE, Kornblith AB, Zuckerman E, Schiffer CA, Weiss RB, Mayer RJ, Wolchok SM, Holland JC
Proc ASCO 14: 508, 1995 *Published Date 1/1/1995*
- 8971 Megestrol acetate for the treatment of cachexia a dose-response trial in patients with advanced lung or colorectal cancers
Parnes H, Conaway MR, Aisner J, Potthoff RF, Kornblith AB, Cooper MR, Kirshner J, Davila E, Szatrowski TP, Ellerton J, Shea TC, Mortimer JE, Maurer LH, Vinciguerra V
Cancer Therapeutics 2:75-82, 1999 *Published Date 8/12/1999*
- 8984 Sphincter sparing treatment for distal rectal adenocarcinoma
Steele GD, Herndon JE, Bleday R, Russell A, Benson AB, Hussain M, Burgess AM, Tepper JE, Mayer RJ
Annals of Surgical Oncology 6(5):443-441, 1999 *Published Date 7/1/1999*
- 8984 Failure and Salvage After Sphincter-Sparing Treatment for Distal Rectal Adenocarcinoma—A CALGB Coordinated Intergroup Study
Steele GD, Tepper JE, Herndon JE, Mayer RJ
Proc ASCO 18:235A-903, 1999 *Published Date 5/15/1999*
- 8984 Sphincter sparing treatment for distal rectal adenocarcinoma: a phase II Intergroup study
Steele GD, Herndon JE, Burgess AM, Bleday R, Russell A, Benson AB, Hussain M, Mayer RJ
Proc ASCO 16:256a, 1997 *Published Date 5/16/1997*
- 8991 Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group
Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Nichols C, Kuzel T, Vaughn D, Wilding G
Journal of Clinical Oncology 20(7):1859-63, 2002 *Published Date 4/1/2002*
- 8991 Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B study
Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ
Journal of Clinical Oncology 16(4):1287-1293, 1998 *Published Date 4/16/1998*

- 9011 Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Martell RE, Peterson BL, Cohen HJ, Peters WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines JD, Larson RA, Schiffer CA, Hurwitz HI
Cancer Chemother Pharmacol 50:37-45, 2002 *Published Date 9/28/2002*
- 9011 Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study CALGB 9011
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shephard L, Larson RA, Schiffer CA
Journal of Clinical Oncology 20(18):3878-3884, 2002 *Published Date 9/15/2002*
- 9011 Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: an intergroup study (CALGB 9011)
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA
Journal of Clinical Oncology 19(16):3611-3621, 2001 *Published Date 8/15/2001*
- 9011 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
Rai KR, Peterson BL, Kolitz JE, Elias L, Shepherd L, Hines JD, Threatte GA, Larson RA, Cheson BD, Schiffer CA
New England Journal of Medicine 343:1750-1757, 2000 *Published Date 12/14/2000*
- 9011 Transformation to Richter's Syndrome or prolymphocytic leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL): An intergroup study (CALGB 9011)
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Hines JD, Shepherd L, Larson RA, Schiffer CA
Blood 94 (10) suppl 1:4013, 1999 *Published Date 11/11/1999*
- 9011 Therapy-Related Myelodysplastic Syndrome (T-MDS) or Acute Myeloid Leukemia (T-AML) in patients with Chronic Lymphocytic Leukemia (CLL) treated with Chlorambucil (C), Fludarabine (F), or Fludarabine + Chlorambucil (F+C): An Intergroup Study (Cancer and Leukemia Group B 9011)
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Hines JD, Shepherd L, Larson RA, Schiffer CA
Proc ASCO 18:9a-29, 1999 *Published Date 5/15/1999*
- 9011 The impact of therapy with chlorambucil (C), fludarabine (F) or fludarabine + chlorambucil (F+C) on infections in patients with chronic lymphocytic leukemia (CLL): an Intergroup Study (CALGB 9011)
Morrison VA, Rai KR, Peterson BA, Kolitz JE, Elias L, Hines JD, Shepherd L, Larson RA, Schiffer CA
Blood 91(10) Suppl:2020, 1998 *Published Date 11/15/1998*
- 9011 A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C, and ECOG Intergroup study.
Rai K, Peterson B, Elias L, Sheperd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA
Blood 88 (10):141a, 1996 *Published Date 1/1/1996*
- 9011 Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). a randomized intergroup study
Rai KR, Peterson B, Kolitz J, Elias L, Shepherd L, Hines J, Cheson B, Schiffer C
Blood 86 (10): 607a, 1995 *Published Date 1/1/1995*
- 9013 Treatment of the chronic phase of CML with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: CALGB 9013
Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA
Leukemia & Lymphoma 44(1):39-48, 2003 *Published Date 1/3/2003*
- 9013 Treatment of chronic myeloid leukemia (CML) with an intermittent schedule of interferon alfa-2B (rlfna-2b) and cytarabine (ara-c): CALGB 9013
Silver RT, Peterson BL, Szatrowski TP, Powell BL, Bloomfield CD, Schiffer CA, Larson RA
Proc ASCO 20:1222, 2001 *Published Date 5/1/2001*
- 9013 Risk factors for severe neuropsychiatric toxicity in patients receiving Interferon-alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of Cancer and Leukemia Group B 9013
Hensley ML, Silver RT, Peterson BL, Larson RA, Szatrowski TP
Journal of Clinical Oncology 18(6):1301-1308, 2000 *Published Date 3/1/2000*
- 9013 Risk factors for severe neuropsychiatric toxicity (NPtoxic) in patients receiving Interferon-Alfa-2b (rIFN- μ) and low-dose cytarabine (AraC) for chronic myeloid leukemia (CML): Analysis of CALGB 9013
Hensley ML, Silver RT, Peterson BL, Larson RA, Szatrowski TP
Proc ASCO 18:415a-1604, 1999 *Published Date 5/15/1999*

- 9013 Combined α -interferon (rIFN α -2b) and low dose cytosine arabinoside (Ara-C) for PH (+) chronic phase chronic myeloid leukemia (CML)
Silver RT, Szatrowski TP, Peterson B, Powell B, Larson R, Stock W, Arthur D, Schiffer C, Bloomfield CD
Blood 88 (10): 638a, 1996 *Published Date 1/1/1996*
- 9021 A Phase III trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia. CALGB 9021
Peterson B, George SL, Bhalla K, Lee E, Carpenter JT, Berk GI, Schiffer CA
Proc ASCO, 1996 *Published Date 1/1/1996*
- 9022 Granulocyte-colony stimulating factor (Filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022
Moore JO, Dodge RK, Amrein PC, Kolitz JE, Lee EJ, Powell BL, Godfrey SA, Robert F, Schiffer CA
Blood 89(3):780-788, 1997 *Published Date 2/1/1997*
- 9031 Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B
Samuels BL, Herndon JE, Harmon D, Carey RW, Aisner J, Corson JJ, Suzuki Y, Green MR, Vogelzang NJ
Cancer 82(8):1578-1584, 1998 *Published Date 4/15/1998*
- 9033 The health-related quality of life in small-cell lung cancer patients: Results of a companion study to CALGB 9033
Naughton MJ, Shumaker SA, Herndon JE, Miller AA, Kornblith AB, Chao D
Quality of Life Research 11:235-248, 2002 *Published Date 9/27/2002*
- 9033 Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B (CALGB 9033)
Miller AA, Herndon JE, Hollis D, Ellerton J, Langleben A, Richard F, Green MR
Journal of Clinical Oncology 13 (8):1871-1879, 1995J Clin Oncol 13(8):1871-1879, 1995 *Published Date 1/1/1995*
- 9041 Subcutaneously administered recombinant human interleukin-2 and interferon α -2a for advanced breast cancer
Kimmick G, Ratain MJ, Berry DA, Woolf S, Norton L, Muss HB
Investigational New Drugs 22:83-89, 2004 *Published Date 8/1/2002*
- 9051 Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin's disease and unfavorable prognostic features: A phase II CALGB Study (9051)
Wasserman TH, Petroni GR, Millard F, Chung C, Barcos MP, Johnson JL, Canellos GP, Peterson BA
Cancer 86(8):1590-1595, 1999 *Published Date 10/15/1999*
- 9051 Etoposide, Vinblastine, and Doxorubicin (EVA) chemotherapy plus subtotal nodal irradiation for early stage, high risk Hodgkin's disease. CALGB 9051
Wasserman TH, Petroni G, Millard F, Chung C, Johnson JL, Canellos GP, Peterson B
Proc ASCO 15: 427, 1996 *Published Date 1/1/1996*

- 9062 Pharmacology of 21-day Oral Etoposide Given in Combination with Intravenous Cisplatin in Patients with Extensive-Stage Small-Cell Lung Cancer: A Cancer and Leukemia Group B Study (CALGB 9062)
Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL
Clinical Cancer Research 3:719-725, 1997 *Published Date 3/1/1997*
- 9062 Pharmacology of 21-day oral etoposide given in combination with intravenous cisplatin for extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 9062)
Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL
Proc ASCO 15: 472, 1996 *Published Date 1/1/1996*
- 9064 Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: A Cancer and Leukemia Group B study
Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker DJ, Skarin AT, Kreisman H, Green MR
Lung Cancer 21:203-211, 1998 *Published Date 9/1/1998*
- 9066 Quality of life among patients w/stage II & III breast carcinoma randomized to receive high-dose chemotherapy w/ autologous bone marrow support or intermediate-dose chemotherapy
Peppercorn J, Herndon JE, Kornblith AB, Peters WP, Ahles TA, Vredenburgh JJ, Schwartz G, Shpall E, Hurd DD, Holland JC, Winer EP
Cancer 104(8):1580-1589, 2005 *Published Date 10/15/2005*
- 9066 Quality of Life in Patients with Breast Cancer Randomized to High Dose Chemotherapy with Bone Marrow Support vs. Intermediate Dose Chemotherapy: CALGB 9066 (Companion protocol to CALGB 9082)
Winer EP, Herndon JE, Peters WP, Brunatti C, Warren K, Vredenburgh JJ, Schwartz GK, Budman DR, Shpall EJ, Henderson IC, Norton L, Hurd DD, Holland JC, Kornblith AB
Proc ASCO 18:412a-1593, 1999 *Published Date 5/15/1999*
- 9072 Recruiting cancer patients to participate in motivating their relatives to quit smoking: a cancer control study of the Cancer and Leukemia Group B (CALGB 9072)
Schilling A, Conaway MR, Wingate PJ, Atkins JN, Berkowitz IM, Clamon GH, DiFino SM, Vinciguerra V
Cancer 79(1):152-160, 1997 *Published Date 1/15/1997*
- 9081 Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson R, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM
Journal of Clinical Oncology 22(10):1773-1775, 2004 *Published Date 4/1/2004*
- 9081 Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from INT-0114
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady DL, O'Connell M, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB, Fuchs CS
Journal of Clinical Oncology 22 (4):648-657, 2004 *Published Date 2/15/2004*
- 9081 Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively-resected rectal cancer
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Fuchs CS
Journal of Clinical Oncology 22 (1):166-174, 2004 *Published Date 1/15/2004*
- 9081 Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup 0114
Tepper JE, O'Connell M, Hollis DR, Niedzwiecki D, Cooke E, Mayer RJ
Journal of Clinical Oncology 21(19):3623-3628, 2003 *Published Date 10/1/2003*
- 9081 Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup 0114/CALGB 9081
Tepper J, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ
Proc ASCO 21:507, 2002 *Published Date 5/2/2002*
- 9081 Adjuvant therapy in rectal cancer: analysis of stage, sex and local control - final report of intergroup 0114/CALGB 9081
Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB, Cummings B, Gunderson LL, MacDonald JS, Martenson JA, Mayer RJ
Journal of Clinical Oncology 20(7):1744-1750, 2002 *Published Date 4/1/2002*

- 9081 Final report of adjuvant therapy in rectal cancer: analysis by treatment, stage, and gender (intergroup 0114)
Tepper J, O'Connell M, Niedzwiecki D, Hollis D, Mayer RJ, III AB, Cummings B, Gunderson LL, MacDonald JS, Martenson JA
 Proc ASCO 20:489, 2001 *Published Date 5/1/2001*
- 9081 Impact of number of nodes retrieved on outcome in patients with rectal cancer
Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis DR, Mayer RJ, Benson AB, Cummings B, Gunderson L, MacDonald JS
 Journal of Clinical Oncology 19:157-163, 2001 *Published Date 1/1/2001*
- 9081 Adjuvant postoperative fluorouracil modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114
Tepper JE, O'Connell MJ, Petroni GR, Hollis DR, Cooke EA, Benson AB, Cummings B, Gunderson L, MacDonald J, Martenson J
 J Clin Oncol 15 (5):2030-2039, 1997 *Published Date 5/1/1997*
- 9081 Toxicity in the adjuvant therapy of rectal cancer:a preliminary report of Intergroup 0114 (CALGB 9081)
Tepper J, O'Connell M, Petroni G, Benson A, MacDonald J, Martenson J, Rich T, Stern H
 Proc ASCO 15:210, 1996 *Published Date 1/1/1996*
- 9082 A prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082
Peters WP, Rosner GL, Vredenburgh JJ, Shpall E, Crump M, Richardson P, Schuster MW, Marks LB, Cirrincione CT, Norton L, Henderson IC, Schilsky RL, Hurd DD
 Journal of Clinical Oncology 23(10):2191-2200, 2005 *Published Date 4/1/2005*
- 9082 The impact of local/regional radiotherapy (RT), and its timing, on survival following lumpectomy/mastectomy and systemic chemotherapy in patients with ≥10 positive axillary nodes: Analysis of CALGB 9082
Marks LB, Cirrincione CT, Peterson BL, Fitzgerald TJ, Laurie F, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Hurd DD, Norton L, Petros WP
 Intl J Radiation Oncoloty, Biology, Physics 60(1):S136, 2004 *Published Date 9/1/2004*
- 9082 Updated results of a prospective randomized comparison of two doses of combination alkylating agents (AA) as a consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN)
Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Hurd D, Norton L
 Proc ASCO 20:81, 2001 *Published Date 5/1/2001*
- 9082 Preliminary analysis of radiotherapy data from CALGB 9082: variability of treatment fields for local/regional breast cancer and the impact of high-dose chemotherapy on the ability to deliver radiation therapy. Proceedings of the 41st annual ASTRO meeting.
Marks LB, Fitzgerald TJ, Laurie F, Glicksman AS, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Hurd DD, Norton L, Peters WP
 Int J Radiat Oncol Biol Phys 45(3)(suppl):94:195, 1999 *Published Date 5/15/1999*
- 9082 A Prospective, Randomized Comparison of Two Doses of Combination Alkylating Agents (AA) as Consolidation After CAF in High-Risk Primary Breast Cancer Involving Ten or More Axillary Lymph Nodes (LN): Preliminary Results of CALGB 9082/SWOG 9114/NCIC MA-13
Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson P, Marks LB, Cirrincione CT, Wood WC, Henderson IC, Hurd DD, Norton L
 Proc ASCO 18:1a-2, 1999 *Published Date 5/15/1999*
- 9091 Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: a preliminary report of intergroup study 113 (RTOG 89-11)
Kelsen DP, Ginsberg RJ, Qian C, Gunderson L, Mortimer JE, Estes N, Hailer D, Ajani JA, Kocha W, Roth J, Minsky BD
 Proc ASCO 16:276a, 1997 *Published Date 5/15/1997*

- 9092 Phase III trial of biochemical modulation of 5-Fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: an ECOG/CALGB phase III trial
O'Dwyer PJ, Ryan LM, Valone FH, Hines JD, Arbuck SG, Wadler S, Haller DG, Mayer RJ, Benson AB
Proc ASCO 15:207, 1996 *Published Date 1/1/1996*
- 9111 A Randomized Controlled Trial of Filgrastim During Re mission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111
Larson RA, Dodge RK, Linker C, Stone RM, Powell BL, Lee EJ, Schulman PP, Davey F, Frankel SR, Bloomfield CD, George SL, Schiffer CA
Blood 92(5):1556-1564, 1998 *Published Date 9/1/1998*
- 9120 Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute MyeloidLleukemia in First Remission
Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH
New England Journal of Medicine 339 (23):1649-1656, 1998 *Published Date 12/3/1998*
- 9120 Comparison of autologous bone marrow transplant (AUTOBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): an ECOG intergroup study
Hurd DD, Cassileth PA, Harrington DP, Paietta E, Lazarus HM, Appelbaum FR, Bennett KJ, Wilman C, Magenis E, Wiernik PH
Proc ASCO 16:89a, 1997 *Published Date 5/1/1997*
- 9130 Radiosensitization wth Carboplatin for Patients With Unresectable Stage III Non Small Cell Lung Cancer: A Phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group
Clamon GH, Herndon JE, Cooper MR, Chang AY, Rosenman J, Green MR
Journal of Clinical Oncology 17(1):4-11, 1999 *Published Date 1/10/1999*
- 9131 Edatrexate (10-ethyl-deaza-aminopterin) (NSC 626715) with or without Leucovorin rescue for malignant mesothelioma: sequential Phase II trials of the Cancer and Leukemia Group B
Kindler HL, Belani C, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR
Cancer 85(10):1985-1991, 1999 *Published Date 11/15/1999*
- 9131 Edatrexate with oral leucovorin rescue for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B - CALGB 9131
Belani CP, Herndon J, Vogelzang NJ, Green MR
Proc ASCO 14: 352, 1995 *Published Date 1/1/1995*
- 9132 A randomized Phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study
Graziano SL, Valone FH, Herndon JE, Crawford J, Richards F, Rege VB, Clamon G, Green MR
Lung Cancer 14(2/3):315-329, 1996 *Published Date 11/1/1996*
- 9133 Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer. A Phase II trial of the Cancer and Leukemia Group B
Clamon GH, Herndon JE, Akerley WL, Green MR
Lung Cancer 19(1):25-29, 1998 *Published Date 1/15/1998*

- 9134 Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer
Elias AD, Kumar P, Herndon JE, Skarin AT, Sugarbaker DJ, Green MR
Clinical Lung Cancer 4(2):95-103, 2002 *Published Date 12/15/2002*
- 9134 A phase III comparison of "best local-regional therapy" with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): Preliminary results
Elias AD, Herndon JE, Kumar P, Sugarbaker DJ, Green MR
Proc ASCO 16:448a-1611, 1997 *Published Date 5/15/1997*
- 9140 A phase III study of CAF+Leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B Study 9140
Parnes H, Berry DA, Aisner J, Allen SL, Abrams J, Cooper MR, Chuang E, Cooper MR, Perry MC, Cirrincione CT, Duggan DB, Szatrowski TP, Henderson IC, Norton L
Journal of Clinical Oncology 21(9):1819-1824, 2003 *Published Date 5/11/2003*
- 9140 A randomized phase III study of cyclophosphamide (C), doxorubicin (A) and 5-fluorouracil (F) (CAF) with and without Leucovorin for metastatic breast cancer: Cancer and Leukemia Group B Study (CALGB) 9140
Parnes H, Berry DA, Aisner J, Allen SL, Abrams J, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Cirrincione CT, Henderson IC, Norton L
Proc ASCO 17:110a-425, 1998 *Published Date 5/15/1998*
- 9141 Clinical outcomes of node-positive breast cancer patients treated with dose-intensified Adriamycin/ cyclophosphamide (AC) followed by Taxol (T) as adjuvant systemic chemotherapy (CALGB 9141)
Demetri GD, Berry DA, Norton L, Broadwater GJ, Robert N, Duggan DB, Henderson IC
Proc ASCO 16:143a, 1997 *Published Date 5/1/1997*
- 9150 High-dose Cyclophosphamide plus Recombinant Human Granulocyte-Colony Stimulating Factor (rhG-CSF) in the treatment of follicular, low-grade Non-Hodgkin's Lymphoma: CALGB 9150
Lichtman SM, Niedzwiecki D, Schilsky RL, Johnson JL, Perri RT, Sklar J, Barcos MP, Peterson BA
Leukemia/Lymphoma 42:1255-1264, 2001 *Published Date 8/1/2001*
- 9155 Pilot trial of cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide + antiretrovirals + G-CSF + erythropoietin in AIDS-associated non-Hodgkin's lymphoma: CALGB 9155
Feigal E, Petroni GR, Freter CE, Johnson JL, Barcos MP, Peterson BA
Proc ASCO 16:56a, 1997 *Published Date 5/1/1997*
- 9160 Evaluation of Amifostine as a Chemoprotective Agent in Combination with Cyclophosphamide and Molgramostin (GM-CSF)
Budman DR, Rosner G, Lichtman S, Miller AA, Ratain MJ, Schilsky RL
Cancer Therapeutics 1(3):164-167, 1998 *Published Date 7/1/1998*
- 9163 Modulation of Vinblastine Resistance in Metastatic Renal Cell Carcinoma with Cyclosporine A or Tamoxifen: A CALGB Study
Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL
Clin Cancer Res 3(11):1977-1984, 1997 *Published Date 11/1/1997*

- 9181 Serum prostate specific antigen as a predictor of survival in patients treated with second-line hormonal therapy: CALGB 9181
Halabi S, Conaway MR, Small EJ, Vogelzang NJ, Dawson NA
The Prostate Journal 3:18-25, 2001 *Published Date 1/1/2001*
- 9181 A Randomized Study Comparing Standard versus Moderately High Dose Megestrol Acetate for Patients with Advanced Prostate Carcinoma: Cancer and Leukemia Group B Study 9181
Dawson NA, Conaway MR, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ
Cancer 88 (4):825-834, 2000 *Published Date 2/15/2000*
- 9181 Prostate Specific Antigen (PSA) as a Predictor of Survival: Cancer and Leukemia Group B (CALGB) 9181
Dawson NA, Halabi S, Hars V, Small EJ, Vogelzang NJ
Proc ASCO 18:314a-1209, 1999 *Published Date 5/15/1999*
- 9181 The Dynamics of Prostate Specific Antigen in Hormone Refractory Prostate Carcinoma: An Analysis of Cancer and Leukemia Group B Study 9181 of Megestrol Acetate
Vollmer RT, Dawson NA, Vogelzang NJ
Cancer 83(9) :1989-1994, 1998 *Published Date 11/1/1998*
- 9181 Megastrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): prostate specific antigen (PSA) response and anti-androgen withdrawal (AAWD) data: Cancer and Leukemia Group B (CALGB) 9181
Dawson, EJS, MC, DL, EP W, MR C, TW, MSE, NJ W
Proc ASCO 15: 241, 1996 *Published Date 1/1/1996*
- 9181 A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a Cancer and Leukmia Group B study
Dawson NA, Conaway M, Winer EP, Lake D, Small EJ, Cooper MR, Green MR, Ernstoff M, Vogelzang NJ
Proc ASCO 14: 236, 1995 *Published Date 1/1/1995*
- 9182 Hydrocortisone With or Without Mitoxantrone in Men With Hormone Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Kantoff PW, Halabi S, Conaway MR, Picus J, Kirshner J, Hars V, Trump DL, Winer EP, Vogelzang NJ
Journal of Clinical Oncology 17 (8):2506, 1999 *Published Date 8/1/1999*
- 9182 Hydrocortisone (HC) with or without mitoxantrone (M) in patients (pts) with hormone refractory prostate cancer (HRPC): preliminary results from a prospective randomized Cancer and Leukemia Group B study (9182) comparing chemotherapy to best supportive care
Kantoff, Conaway M, Winer E, Picus J, Vogelzang NJ
Proc ASCO 14 (5): 1748, 1996 *Published Date 1/1/1996*
- 9191 Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on intergroup 0129 and pethema LPA96 and LPA99
Tallman M, Kim HT, Schiffer CA, Appelbaum F, Feusner JH, Ogden AK, Shepherd L, Willman CL, Bloomfield CD, Rowe JM, Larson RA, Wiernik PH, Martin G, Rayon C, delSerna J, Rivas C, Gonzalez-SanMiguel JD, Deben G, Sanz MA
Blood 104(11):394, 2004 *Published Date 12/1/2004*
- 9191 All-trans-retinoic acid in acute promyelocytic leukemia: longterm outcome and prognosis factor analysis from the North American Intergroup protocol
Tallman MS, Anderson JW, Schiffer CA, Appelbaum FR, Feusner JH, Wood W, Ogden A, Weinstein H, Shepherd L, William C, Bloomfield CD, Rowe JM, Wiernik PH
Blood 100(13):4298-4302, 2002 *Published Date 12/15/2002*
- 9191 Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARa Isoform: Results from Intergroup Protocol 0129
Slack JL, Willman C, Andersen JW, Li Y, Viswanatha D, Bloomfield CD, Tallman MS, Gallagher RE
Blood 95:398-403, 2000 *Published Date 10/15/2000*
- 9191 Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, ECOG, CALGB intergroup study
Willman CL, Yeap B, Bi W, Slack JL, DP H, Livak KJ, Appelbaum FR, Bloomfield CD, Tallman MS, Gallagher RE
Proc ASCO 19:5a, 2000 *Published Date 5/15/2000*

- 9191 Clinical description of 44 patients with Acute Promyelocytic Leukemia who developed Retinoic Acid syndrome
Tallman MS, Anderson JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shephard L, Rowe JM, Francois C, Larson RA, Wiernak PH
Blood 95(1):90-95, 2000 *Published Date 1/1/2000*
- 9191 All-Trans Retinoic in Acute Promyelocytic Leukemia; long term outcome results and prognostic factor analysis from intergroup protocol 0129
Tallman MS, Anderson JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH
Blood 94:168a, 1999 *Published Date 11/11/1999*
- 9191 All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernick PH
New Eng J Med 337(15):1021-1028, 1997 *Published Date 10/9/1997*
- 9191 Association of PML-RARa fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia (APL): an intergroup molecular study
Gallagher RE, Willman C, Slack JL, Anderson J, Li Y, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH
Blood 90(4):1656-1663, 1997 *Published Date 8/15/1997*
- 9191 Secondary cytogenetic changes in acute promyelocytic leukemia: prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene. A Cancer and Leukemia Group B study
Slack JL, Arthur DC, Lawrence D, Mrozek KA, Mayer RJ, Davey F, Tantravahi RR, Pettenati MJ, Bigner SH, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD
J Clin Oncol 15(5):1786-1795, 1997 *Published Date 5/1/1997*
- 9192 Effect of chemohormonal therapy in premenopausal node (+) receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101)
Davidson N, O'Neill A, Vukov A, Osborne CK, Martino S, White DD, Abeloff MD
Proc ASCO:15, 2003 *Published Date 5/15/2003*
- 9192 Effect of chemohormonal therapy in premenopausal node (+) receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101)
Davidson N, O'Neill A, Vukov A, Osborne CK, Martino S, White DD, Abeloff MD
Proc ASCO 18:67a-249, 1999 *Published Date 5/15/1999*
- 9193 Sixteen Week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an intergroup study
Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron M, Grove-Conrad M, Cella DF, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD
Journal of Clinical Oncology 16(7):2382-2391, 1998 *Published Date 7/15/1998*
- 9193 CAF vs a 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: an intergroup study
Fetting J, Gray R, Abeloff M, Fowble B, Smith T, Vail S, Durrani G, Budey L, Heaney J, Margolin K, Citron M, Osborne C, Henderson C
Proc ASCO 14: 96, 1995 *Published Date 1/1/1995*

- 9194 Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG 8814/CALGB 9194)
Albain K, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, Osborne CK
Proc ASCO 21:143, 2002 *Published Date 5/1/2002*
- 9194 Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to tamoxifen alone in postmenopausal, receptor (+), node (+) breast cancer: New findings from Phase III SWOG intergroup trial S8814 (INT 0100)
Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Lew D, Martino S, Osborne CK
Proc ASCO 20:94, 2001 *Published Date 5/2/2001*
- 9195 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction: a phase III Intergroup study 0116/CALGB 9195/SWOG 9008
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA
New England Journal of Medicine 345:725-730, 2001 *Published Date 9/6/2001*
- 9196 CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: a Phase III Intergroup Trial (SWOG-8897, INT-0102)
Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff MD, Lyss AP, Henderson IC, Allred DC, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K
22nd Annual San Antonio Breast Cancer Symposium Dec 8-11, 1999 *Published Date 12/8/1999*
- 9196 CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102
Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff MD, Lyss AP, Henderson IC, Allred DC, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne CK
Proc ASCO 16:2, 1997 *Published Date 5/15/1997*
- 9211 A phase II study of cladribine treatment for fludarabine refractory B-cell chronic lymphocytic leukemia: results from CALGB study 9211
Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C
Leukemia 17:323-327, 2003 *Published Date 12/1/2003*
- 9211 Cladribine has Clinical Activity in Patients with Fludarabine Refractory Chronic Lymphocytic Leukemia who Lack Pre-Treatment Cytopenias
Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer CA
Blood 98:2654, 2001 *Published Date 11/1/2001*
- 9221 Analysis of survival, AML transformation, and transfusion independence in patients with high-risk myelodysplastic syndrome receiving azacitidine determined using a prognostic model
Silverman LR, McKenzie DR, Peterson BL, Demakos EP, Holland JF, Larson RA
Blood 106(11):2523, 2005 *Published Date 11/15/2005*
- 9221 A new validated myelodysplastic syndrome prognostic model for use when cytogenetics are unavailable
Silverman LR, Germing U, McKenzie DR, Peterson BL, Larson RA
Blood 106(11):2527, 2005 *Published Date 11/15/2005*
- 9221 Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome patients > 65 years of age
Silverman LR, McKenzie DR, Peterson BL, Demakos EP, Malone N, Holland JF, Larson RA
Blood 106(112):2524, 2005 *Published Date 11/15/2005*
- 9221 Rates of infection and bleeding are not increased in patients with myelodysplastic syndromes treated with azacitidine compared with supportive care
Silverman LR, McKenzie DR, Peterson BL, Odchimar-Reissig R, Hinkle R, Backstrom JT, Larson RA
Blood 106(11):2525, 2005 *Published Date 11/15/2005*

- 9221 Impact of Azacytidine on the quality of life of patients with Myelodysplastic Syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B Study
Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JC
Journal of Clinical Oncology 20(10):2441-2452, 2002 *Published Date 5/15/2002*
- 9221 Randomized controlled trial of Azacitidine in patients with the myelodysplastic syndrome: a Study of the Cancer and Leukemia Group B (9221)
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson DA, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF
Journal of Clinical Oncology 20(10):2429-2440, 2002 *Published Date 5/15/2002*
- 9221 A Randomized Controlled Trial of Subcutaneous Azacytidine (AZA C) in Patients With the Myelodysplastic Syndrome (MDS): A Study of the Cancer and Leukemia Group B (CALGB)
Silverman LR, Demakos EP, Peterson BL, Odchimar-Reissig R, Nelson DA, Kornblith AB, Stone RM, Holland JC, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF
Proc ASCO 17:14a-53, 1998 *Published Date 5/15/1998*
- 9221 The Impact of 5-Azacytidine on the Quality of Life of Patients With the Myelodysplastic Syndrome (MDS) Treated in a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB)
Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JC
Proc ASCO 17:49a-189, 1998 *Published Date 5/15/1998*
- 9222 Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222
Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey F, Bloomfield CD, Larson RA, Schneider CJ
Blood 105(9):3420-3427, 2005 *Published Date 5/1/2005*
- 9222 A comparison of sequential non-cross resistant therapy or ARA-C consolidation following complete remission in adult patients less than 60 years with acute myeloid leukemia: CALGB 9222
Moore JO, Powell BL, Velez-Garcia E, Kolitz JE, George SL, Dodge RK, Rizzieri DA, Schiffer CA
Proc ASCO 16:14a, 1997 *Published Date 5/1/1997*
- 9232 Free riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials
Bennett CL, Smith TJ, George SL, Hillner BE, Fleishman S, Niell HB
J Clin Oncol 13: 2457-2463,1995 *Published Date 1/1/1995*
- 9234 High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
Vogelzang NJ, Herndon JE, Miller AA, Strauss GM, Clamon GH, Stewart FM, Aisner J, Lyss AP, Cooper MR, Suzuki Y, Green MR
Annals of Oncology 10:597-600, 1999 *Published Date 5/1/1999*
- 9235 A phase III trial evaluating the combination of cisplatin, etoposide, radiation therapy with or without tamoxifen in patients with limited stage small cell lung cancer
McClay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagreen S, Green M
American Journal of Clinical Oncology 28(1):81-90, 2005 *Published Date 2/28/2005*
- 9235 Interruptions of modest dose once-daily (QD) thoracic radiotherapy (TRT) do not correlate with outcome in limited small cell lung cancer (L-SCLC): analysis of CALGB 9235
Bogart JA, Watson DM, McClay EF et al
Proc American Radium Society, 2003 *Published Date 6/23/2003*

- 9236 Dose intensive non-cross resistant alternating therapy for limited stage small cell lung cancer: A CALGB phase II trial
Westgate SJ, Lilenbaum RC, Herndon JE, Crawford J, Perry MC, Green MR
Proc ASCO 17:504a-1944, 1998 *Published Date 5/15/1998*
- 9242 Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study
Levine E, Cirincione CT, Szatrowski TP, Canellos GP, Norton L, Henderson IC
Am J Clin Oncol 22(3):218-222, 1999 *Published Date 7/14/1999*
- 9251 Burkitt leukemia and lymphoma are curable with short course of intensive chemotherapy
Rizzieri DA, Johnson JL, Larson RA
The American Journal of Oncology Review 3(8):475-481, 2004 *Published Date 8/2/2004*
- 9251 Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B study 9251
Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA
Cancer 100(7):1438-1448, 2004 *Published Date 4/1/2004*
- 9251 Brief duration high intensity chemotherapy for patients with small non-cleaved lymphoma or FAB L-3 acute lymphocytic leukemia: Results of CALGB 9251
Lee EJ, Petroni GR, Freter CE, Johnson JL, Barcos MP, Frizzera G, Bloomfield CD, Schiffer CA, Peterson BA
Journal of Clinical Oncology 19(20):4014-4022, 2001 *Published Date 10/15/2001*
- 9251 Efficacy and toxicity of brief duration, high intensity chemotherapy for small noncleaved cell lymphoma/L-3 ALL: results of CALGB 9251
Rizzieri DA, Johnson J, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Schiffer CA, Peterson BA, Canellos GP, Larson RA
Blood 96 (suppl 1):829a #3582, 2000 *Published Date 10/31/2000*
- 9251 Brief duration high intensity chemotherapy (CT) for for patients with small non-cleaved lymphoma and FAB L3 acute lymphocytic leukemia in adults: Preliminary results of CALGB 9251
Lee EJ, Petroni GR, Freter CE, Johnson JL, Schiffer CA, Peterson BA
Proc ASCO 16:24a, 1997 *Published Date 5/1/1997*
- 9254 Anti-B4-Blocked-Ricin (NSC#639185) adjuvant therapy post-autologous bone marrow transplant: a phase III study
Grossbard ML, Niedzwiecki D, Nadler LM, Fruchtmann SM, Schuster M, Pecora A, Lazarus HM, Johnson JL, Peterson BA, Hurd DD
Proc ASCO 17:3a-8, 1998 *Published Date 5/15/1998*
- 9255 Phase II study of infusional chemotherapy with doxorubicin, vincristine, and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive Non-Hodgkin's Lymphoma: CALGB 9255
Lichtman SM, Niedzwiecki D, Barcos MP, Carlisle TL, Cooper MR, Johnson JL, Peterson BA
Annals of Oncology 11:1141-1146, 2000 *Published Date 11/27/2000*
- 9255 Phase II study of infusional chemotherapy with doxorubicin, vincristine, and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255
Lichtman SM, Niedzwiecki D, Carlisle TL, Cooper MR, Johnson JL, Peterson BA
Proc ASCO 17:30a -117, 1998 *Published Date 5/15/1998*

- 9256 Phase II Trial of Docetaxel in Non-Hodgkin's Lymphomas: A study of the Cancer and Leukemia Group B
Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos MP, Peterson BA
J Clin Oncol 15(10):3275-3279, 1997 *Published Date 11/15/1997*
- 9256 CALGB 9256: a phase II trial of docetaxel in non-Hodgkin's lymphoma patients
Budman DR, Petroni GR, Cooper MR, Johnson JL, Peterson BA
Proc ASCO 15:411, 1996 *Published Date 1/1/1996*
- 9264 Phase I and Pharmacokinetic Trial of Paclitaxel in Patients with Hepatic Dysfunction: Cancer and Leukemia Group B 9264
Venook AP, Egorin M, Rosner GL, Brown TD, Jahan T, Batist G, Hohl RJ, Budman DR, Ratain MJ, Kearns CM, Schilsky RL
Journal of Clinical Oncology 16 (5):1811-1819, 1998 *Published Date 5/15/1998*
- 9267 Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III Non-Small Cell Lung Cancer: A Cancer and Leukemia Group B Study
Graziano SL, Tatum A, Herndon JE, Box JW, Memoli V, Kern JA
Lung Cancer 33(2-3):115-123, 2001 *Published Date 9/1/2001*
- 9270 Aspirin for the prevention of colorectal adenomas in patients with previous colorectal cancer: A randomized controlled trial: results of CALGB study 9270
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Schilsky RL
New England Journal of Medicine 348(10):883-890, 2003 *Published Date 3/6/2003*
- 9270 Quality of colonoscopy reporting: A process of care study
Robertson DJ, Lawrence LB, Shaheen NJ, Baron JA, Paskett E, Petrelli NJ, Sandler RS
American Journal of Gastroenterology 97(10):2651-2656, 2002 *Published Date 10/30/2002*
- 9270 Use of vitamins, minerals and nutritional supplements by participants in a chemoprevention trial
Sandler RS, Halabi S, Kaplan EB, Baron JA, Paskett ED, Petrelli NJ
Cancer 91:1040-1045, 2001 *Published Date 2/15/2001*
- 9281 Combined-modality therapy of poor-prognosis anal carcinoma: a phase II study of CALGB
Meropol NJ, Niedzwiecki D, Shank BM, Colacchio T, Ellerton J, Valone FH, Hollis DR, Budinger SC, Mayer RJ
Proc Gastrointestinal Cancers Symposium:238, 2005 *Published Date 1/27/2005*
- 9281 Combined-modality therapy of poor-risk anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B
Meropol NJ, Niedzwiecki D, Shank BM, Colacchio T, Ellerton J, Valone FH, Hollis DR, Budinger SC, Mayer RJ
Proc ASCO 18:237a-909, 1999 *Published Date 5/15/1999*
- 9293 Phase III Double-Blind Randomized Trial of 13-Cis-Retinoic Acid (13-CRA) to Prevent Second Primary Tumors (SPT's) in Stage I Non-Small Cell Lung Cancer
Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse C, Williams B, Perez C
J Natl Cancer Inst 93(8):605-618, 2001 *Published Date 4/18/2001*

- 9294 A Phase III Study of Adjuvant Radiation Therapy (RT), 5-Fluorouacil (5-FU) and Levamisole (LEV) Vs 5-FU and LEV in Selected Patients With Resected, High-Risk Colon Cancer: Initial Results of Int 0130
Martenson J, Willet C, Sargent D, Goldberg RR, Gunderson L, Myerson RJ, Thomas P, Fisher B, Benson AB
Proc ASCO 18:235a-904, 1999 *Published Date 5/15/1999*
- 9311 Lineage-specific treatment of adult patients with acute lymphoblastic leukemia in first remission with Anti-B4-blocked Ricin or high-dose Cytarabine: CALGB 9311
Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart C, Hurd D, Kolitz JE, Velez-Garcia E, Bloomfield CD, Schiffer CA, Larson RA
Cancer 97(6):1471-1480, 2003 *Published Date 3/15/2003*
- 9312 Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321
Barlogie B, Kyle R, Anderson KC, Greipp P, Lazarus H, Hurd DD, McCoy J, Dakhil S, Lanier K, Chapman R, Cromer JN, Salmon S, Durie BG, Crowley J
Journal of Clinical Oncology 24(6):929-936, 2006 *Published Date 2/20/2006*
- 9312 Genetic polymorphisms associated with clinical outcome in the intergroup trial S9321, comparing high dose therapy with standard dose therapy for myeloma on behalf of ECOG, SWOG, CALGB, and the Bank on a Cure
Santana-Davila R, Crowley J, Durie BG, Barlogie B, Greipp P, VanNess B
Blood 104(11):1495, 2004 *Published Date 12/1/2004*
- 9332 A phase II trial of vinorelbine (NVB) plus doxorubicin in relapsed small cell lung cancer
Johnson EA, Lake D, Herndon JE, Box JW, Lynch TJ, Green MR
American Journal of Clinical Oncology 27(1):19-23, 2004 *Published Date 2/14/2004*
- 9332 Phase II trial of Navelbine (NVB) plus doxorubicin (DOX) in relapsed small cell lung cancer (SCLC)
Johnson EA, Lake D, Herndon JE, Green MR
Proc ASCO 16:471a-1696, 1997 *Published Date 5/15/1997*
- 9332 Phase II Trial of Navelbine® (NVB) in Relapsed Small Cell Lung Cancer (SCLC)
Lake D, Johnson EA, Herndon JE, Green MR
Proc ASCO 16:473a-1703, 1997 *Published Date 5/15/1997*
- 9334 A phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusion (CALGB 9334)
Dresler C, Olak J, Herndon JE, Richards W, Scalzetti E, Fleishman S, Kernstine KH, Demmy TL, Jablons DM, Kohman LJ, Sugarbaker DJ, Daniel T, Haasler G
Chest 127(3):909-915, 2005 *Published Date 3/3/2005*
- 9334 Quality of life (QOL) advantage of sclerosis for malignant pleural effusion (MPE) via talc thoracoscopy over chest tube infusion of talc slurry: Cancer and Leukemia Group B study 9334
Fleishman SB, Dressler C, Herndon JE, Kornblith AB, Kernstine K, Perry M, Jablons D, Sugarbaker D, Haasler G, Daniel TM
Proc ASCO 21:1418, 2002 *Published Date 4/26/2002*
- 9335 Video assisted wedge resection (VAR) and local radiotherapy for peripheral lung cancer in high risk patients: CALGB 9335 a phase II study
Shennib H, Bogart J, Herndon JE, Kohman L, Keenan R, Green M, Sugarbaker D
Journal of Thoracic and Cardiovascular Surgery 129(4):813-818, 2005 *Published Date 4/1/2005*
- 9335 A prospective multi-center phase II trial of thorascopic wedge resection and radiotherapy for stage I high-risk patients: final report CALGB 9335
Shennib H, Bogart J, Herndon JE, Kohman L, Green M, Keenan R, Sugarbaker D
Program American Association for Thoracic Surgery 82 Annual Mtg AATS, 2002 *Published Date 4/2/2002*
- 9335 Thorascopic wedge resection and radiotherapy for T1N0 non-small cell lung cancer (NSCLC) in high risk patients: preliminary analysis of a Cancer and Leukemia Group B and Eastern Cooperative Oncology Group Phase II trial
Bogart JA, Shennib H, Kohman LJ, Sugarbaker DJ, Keenan R, Fitzgerald TJ, Turrisi AT, Herndon JE, Green MR
Proc ASCO 19:488a-1907, 2000 *Published Date 5/15/2001*

- 9342 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: results from CALGB 9342
Winer E, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss HB, Norton L
 Journal of Clinical Oncology 22(11):2061-2068, 2004 *Published Date 6/1/2004*
- 9342 The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342
Lin NU, Broadwater G, Dressler LG, Schnitt S, Lara JF, Bleiweiss JJ, Ngo T, Miron A, Winer EP, Harris LN
 Proc ASCO:9562, 2004 *Published Date 5/1/2004*
- 9342 Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer- Results From CALGB 9342
Winer EP, Berry DA, Duggan DB, Henderson IC, Cirrincione CT, Cooper MR, Norton L
 Proc ASCO 17:101a-388, 1998 *Published Date 5/15/1998*
- 9343 A randomized comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) carcinoma of the breast: results of CALGB study 9343
Hughes KS, Schnaper L, Berry DA, Cirrincione CT, McCormick B, Shank B, Wheeler JD, Champion L, Smith T, Smith BL, Shapiro CL, Muss HB, Winer EP, Hudis CA, Wood W, Sugarbaker DJ, Henderson IC, Norton L
 New England Journal of Medicine 351(10):971-977, 2004 *Published Date 9/2/2004*
- 9343 Comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) carcinoma of the breast
Hughes KS, Schnaper L, Berry D, Cirrincione C, McCormack B, Lu JD, Smith T, Smith B, Shank B, Shapiro C, Henderson IC, Norton L
 Proc ASCO 20:93, 2001 *Published Date 5/1/2001*
- 9343 Carcinoma of the breast in the geriatric population
Shank BM, Inouye P, Schnaper L, Buyske J, Shapiro CL, Berry DA, Wilder KL, Hughes KS
 Surgical Rounds Jan:p16-20, 1997 *Published Date 1/15/1997*
- 9344 Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344
Sartor C, Peterson BL, Woolf SH, Fitzgerald TJ, Laurie F, Turrisi AJ, Bogart JA, Henderson IC, Norton L
 Journal of Clinical Oncology 23(1):30-40, 2005 *Published Date 1/1/2005*
- 9344 Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344
Sartor CI, Fitzgerald TJ, Laurie F, Peterson BL, Woolf S, Henderson IC, Turrisi AT, Muss HB, Norton L
 Proc ASCO abstract #38, 2003 *Published Date 5/31/2003*
- 9344 Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein L, Martino S, Ingle JN, Cooper MR, Hayes DF, Borden EC, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L
 Journal of Clinical Oncology 21(6):976-983, 2003 *Published Date 3/15/2003*
- 9344 Does addition of taxol after adjuvant adriamycin/cytosan chemotherapy affect local recurrence in patients treated with breast conserving therapy?
Sartor C, Henderson IC
 Proc ASTRO, 2000 *Published Date 5/15/2000*
- 9344 Cost-effectiveness of the sequential addition of paclitaxel to doxorubicin plus cyclophosphamide in the adjuvant chemotherapy of patients with node positive breast cancer
Annemans L, Moermans K, Martin C, Norton L, Henderson IC
 Proc ASCO 19:8 Onc Forum, 2000 *Published Date 5/20/2000*

- 9344 Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC).
Henderson IC, Berry DA, Demetri GD, Cirincione CT, Goldstein L, Martino S, Ingle JN, Cooper MR, Canellos GP, Borden EC, Fleming G, Holland JF, Graziano SL, Carpenter JT, Muss HB, Norton L
Proc ASCO 17:101a-390A, 1998 *Published Date 5/15/1998*
- 9351 High dose CHOP induction therapy for poor prognosis aggressive NHL (CALGB 9351: FFP differs at high and low accrual institutions
Shipp MA, Niedzwiecki D, Johnson JL, Janicek M, Barcos MP, Gockerman JP, Peterson BA
Blood 92(10) Suppl:#2005, 1998 *Published Date 11/15/1998*
- 9362 Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B Study
Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL
J Clin Oncol 13(9):2230-2237, 1995 *Published Date 1/1/1995*
- 9364 Can social support reduce breast cancer patients' psychological distress when faced with stressful life events?
Kornblith AB, Herndon JE, Zuckerman EL, Viscoli CM, Horwitz RI, Weiss RB, Cooper MR, Crawford J, Borden EC, Perry MC, Budman DR, Norton L, Holland JC
Proc ASCO 18:589a-2276, 1999 *Published Date 5/15/1999*
- 9364 Social support as a buffer to stressful life events in the psychosocial adjustment of breast cancer patients
Kornblith AB, Herndon JE, Zuckerman EL, Viscoli CM, Horwitz RI, Cooper MR, Harris LN, Tkaczuk KH, Perry MC, Budman DR, Norton L, Holland JC
Cancer 91(2):443-454, 2001 *Published Date 1/15/2001*
- 9380 An analysis of multiple staging management strategies for carcinoma of the esophagus: Computed tomography, endoscopic ultrasound, positron emission tomography and thoracoscopy/laparoscopy: CALGB 9380
Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman B, Reed CE
Annals of Thoracic Surgery 74(4):1026-1032, 2002 *Published Date 10/12/2002*
- 9380 A prospective trial of the feasibility of thoracoscopy/laparoscopy in staging for esophageal cancer: a phase II study
Krasna MJ, Reed CE, Nedzwiecki D, Hollis DR, Luketich JD, DeCamp M, Mayer RJ, Sugarbaker DJ
Annals of Thoracic Surgery 71(4):1073-1079, 2001 *Published Date 4/5/2001*
- 9380 The feasibility of thoracoscopy/laparoscopy in the staging of esophageal cancer: Results of a prospective multicenter phase II trial (CALGB 9380)
Krasna MJ, Reed CE, Hollis DR, Niedzwiecki D, Luketich J, DeCamp MM, Mayer RJ, Sugarbaker DJ
Proc ASCO 19:924, 2000 *Published Date 5/15/2000*
- 9391 A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage I-IIA Hodgkin's disease: SWOG 9133, CALGB 9391
Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI
Journal of Clinical Oncology 19(22):4238-4244, 2001 *Published Date 11/15/2001*

- 9394 Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137/CALGB 9394/SWOG 9313)
Haskell CM, Green SJ, Sledge GW, Shapiro CL, Ingle JN, Lew D, Martino S, Livingston R, Osborne CK
Proc ASCO 21:36a (#142), 2002 *Published Date 5/1/2002*
- 9396 A comparison of laparoscopically assisted colectomy and open colectomy for colon cancer
The Clinical Outcomes of Surgical Therapy Study Group: Nelson H, Sargent DJ, Wieand HS, Fleshman J, Anvari M, Stryker S, Beart R, Hellinger M, Flanagan R, Peters W, Ota D
New England Journal of Medicine 350:2050-2059, 2004 *Published Date 5/13/2004*
- 9396 Short term quality-of-life outcomes following laparoscopic-assisted colectomy versus open colectomy for colon cancer: a randomized trial
Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G
JAMA 287(3):321-328, 2002 *Published Date 1/16/2002*
- 9396 Early results of laparoscopic surgery for colorectal cancer
Fleshman, Nelson H, Peters WR, Kim HC, Larach S, Boorse RR, Ambroze W, Leggett P, Bleday R, Stryker S, Christenson B, Wexner S, A S, DR, JS, AP F
Dis Colon Rectum 39: S53-S58, 1996 *Published Date 1/1/1996*
- 9411 Measuring costs and clinical outcomes from prospective clinical trial and retrospective financial databases: experience gained from Cancer and Leukemia Group B study 9411.
Smith TJ, Herndon JE, Larson RA, Schiffer CA, McDonald K, Penberthy L, Weeks JC
Proc ASCO 16:420a, 1997 *Published Date 5/1/1997*
- 9420 Post remission therapy with low-dose Interleukin-2 with or without intermediate pulse dose Interleukin-2 therapy is well tolerated in elderly patients with Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420
Farag SS, George SL, Lee EJ, Dodge RK, Becknell B, Fehniger T, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA
Clinical Cancer Research 8:2812-2819, 2002 *Published Date 9/15/2002*
- 9420 Daily low dose interleukin 2 (IL-2) therapy with or without intermediate dose pulsing in acute myeloid leukemia (AML) patients \geq 60 years old in first complete remission (CR1): feasibility study (CALGB 9420)
Caligiuri MA, Lee EJ, Baer MR, Dodge R, Cooke K, Szatrowski T, Schiffer CA, Bloomfield CD, Larson RA
Blood 94 (supl 1):76a, 1999 *Published Date 11/11/1999*
- 9420 Parallel phase I studies of Daunorubicin given with Cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420
Lee EJ, George SL, Caligiuri MA, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith RG, Baer MR, Schiffer CA
Journal of Clinical Oncology 17 (9):2831-2839, 1999 *Published Date 9/1/1999*
- 9420 A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and Leukemia Group B (CALGB) study 9420
Lee EJ, George SL, Caligiuri MA, Dodge RK, Smith RG, Szatrowski TP, Schiffer CA
Blood 90(10) Suppl:506a-2256, 1997 *Published Date 11/15/1997*

- 9430 Novel doublets in extensive small cell lung cancer: a randomized phase II study of topotecan/cisplatin, paclitaxel/cisplatin and paclitaxel/topotecan
Lyss AP, Herndon JE, Lynch TJ, Turisi AT, Watson D, Grethlein SJ, Green MR
Clinical Lung Cancer 3:205-210, 2002 *Published Date 2/13/2002*
- 9430 Paclitaxel (P) + cisplatin (C) + G-CSF (G) in patients with previously untreated extensive stage small cell lung cancer (E-SCLC): Preliminary analysis of CALGB 9430
Lyss AP, Herndon JE, Lynch TJ, Mauer AM, Green MR
Proc ASCO 18:468a-1806, 1999 *Published Date 5/15/1999*
- 9430 Toxicity of paclitaxel (P) and topotecan (T) in patients with previously untreated extensive small cell lung cancer (E-SCLC)
Lynch TJ, Herndon JE, Lilenbaum RC, Lyss A, Miller AA, Green MR
Proc ASCO 18:515a-1987, 1999 *Published Date 5/15/1999*
- 9431 Randomized phase II study of Cisplatin with Gemcitabine or Paclitaxel, or Vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for Stage IIIB Non-Small Cell Lung Cancer
Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR
Journal of Clinical Oncology 20(20):4191-4198, 2002 *Published Date 10/15/2002*
- 9431 A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind C) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB 9431)
Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR
Proc ASCO 18:459a-1771, 1999 *Published Date 5/15/1999*
- 9431 Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer
Vokes EE, Leopold KA, Herndon JE, Green MR
Sem Oncol 24(3):S8-42-S8-45, 1997 *Published Date 6/1/1997*
- 9431 A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Inc CT) and concomitant chemoradiotherapy (XRT) in Stage IIIB non-small cell lung cancer (NSCLC): feasibility data (CALGB study 9431)
Vokes EE, Leopold KA, Herndon JE, Crawford J, Cooper MR, Clamon GH, Epstein J, Green MR
Proc ASCO 16:455a, 1997 *Published Date 5/1/1997*
- 9462 Phase I and pharmacological study of continuous infusion Topotecan in combination with Cisplatin in patients with advanced cancer: Cancer and Leukemia Group B study 9462
Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin M, Schilsky RL, Ratain MJ
Journal of Clinical Oncology 16(10):3302-3309, 1998 *Published Date 10/16/1998*
- 9462 Pharmacologic study of continuous infusion topotecan and cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B study (CALGB 9462)
Miller AA, Egorin M, Lilenbaum RC, Hollis DR, Rosner GL, Batist G, Bernard S, Schilsky RL, Ratain MJ
Proc ASCO 16:200a, 1997 *Published Date 5/1/1997*
- 9462 Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462)
Lilenbaum RC, Miller AA, Batist G, Hollis DR, Rosner GL, Schilsky RL, Ratain MJ
Proc ASCO 15: 485, 1996 *Published Date 1/1/1996*

- 9473 Phase II study of fish oil capsules for patients with cancer cachexia; a Cancer and Leukemia Group B study
Burns CP, Halabi S, Clamon GH, Kaplan EB, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett ED
Cancer 101(2):370-378, 2004 *Published Date 7/15/2004*
- 9473 Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia; a Cancer and Leukemia Group B study
9473
Burns CP, Halabi S, Clamon GH, Hars V, Wagner B, Hohl RJ, Lester EP, Kirshner J, Vinciguerra V, Paskett ED
Clinical Cancer Research 5:3942-3947, 1999 *Published Date 12/1/1999*
- 9480 The prognostic significance of plasma chromogranin A levels hormone-refractory prostate cancer patients treated on CALGB 9480
Taplin ME, George DJ, Halabi S, Sanford BL, Febbo PG, Hennessey KT, Mihos CG, Small EJ, Kantoff PW
Urology 66(2):386-391, 2005 *Published Date 8/2/2005*
- 9480 The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from CALGB 9480
George DJ, Halabi S, Shepard TF, Sanford BL, Vogelzang NJ, Small EJ, Kantoff PW
Clinical Cancer Research 11:1815-1820, 2005 *Published Date 3/1/2005*
- 9480 Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of intergroup 0159/CALGB 9480
Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler WM, Palchak DL, Marshall ME, Wilding G, Petrylak D, Holland JC
Cancer 101(10):2202-2208, 2004 *Published Date 11/15/2004*
- 9480 Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480
Taplin ME, George DJ, Halabi S, Sellers WR, Sanford BL, Hennessey KT, Mihos CG, Small EJ, Kantoff PW
Proc ASCO:4557, 2004 *Published Date 5/1/2004*
- 9480 Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of CALGB 9480/Intergroup 0159
Small EJ, Halabi S, Ratain MJ, Rosner G, Ansari R, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ
Journal of Clinical Oncology 20 (16):3369-3375, 2002 *Published Date 8/15/2002*
- 9480 Prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in men with hormone refractory prostate cancer (HRPC)
Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ
Journal of Clinical Oncology 19(12):3025-3028, 2001 *Published Date 7/15/2001*
- 9480 Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone-refractory prostate cancer: CALGB 9480
George DJ, Halabi S, Shepard TF, Hayes DF, Vogelzang NJ, Small EJ, Kantoff PW
Clinical Cancer Research 7(7):1932-1936, 2001 *Published Date 7/15/2001*
- 9480 VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study
Bok RA, Halabi S, Fei DT, Rodriguez CR, Hayes DF, Vogelzang NJ, Kantoff PW, Shuman MA, Small EJ
Cancer Research 61:2533-2536, 2001 *Published Date 3/15/2001*
- 9480 RT-PCR for prostate specific antigen (PSA) in peripheral blood (PB) predicts survival duration in patients with hormone refractory prostate cancer (HRPC)—A CALGB study
Kantoff PW, Halabi S, Farmer D, Hayes DF, Vogelzang NJ, Small EJ
Proc ASCO 19:336a-1323, 2000 *Published Date 5/20/2000*
- 9480 VEGF and basic FGF urine levels as predictors of response to therapy with Suramin in CALGB 9480, a Phase III study of Hormone Refractory Prostate Cancer (HRPC) patients
Bok RA, Halabi S, Shaal M, Fei DT, Rodriguez C, Hayes DF, Vogelzang NJ, Small EJ
Proc ASCO 19:347a-1367, 2000 *Published Date 5/20/2000*
- 9480 Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC).
Halabi S, Small EJ, Ansari RH, Wilding G, Petrylak D, Palchak DL, Marshall E, Rago R, Hars V, Vogelzang NJ
Proc ASCO 19:328a-1291, 2000 *Published Date 5/20/2000*

- 9480 A phase III trial of 3 different doses of suramin (SUR) in metastatic hormone refractory prostate cancer (HRPC): Safety profile of CALGB 9480
Vogelzang NJ, Small EJ, Halabi S, Ansari RH, Palchak DL, Rago R, Cooper MR, Hudson J, Schultz PK, Hars V
 Proc ASCO 17:347a-1339, 1998 *Published Date 5/15/1998*
- 9481 Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, cost effectiveness and molecular markers
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz H, Warren RS, Naughton MJ, Weeks JC, Herndon JE, Zhang C, Mayer RJ
 Journal of Clinical Oncology 24(9):1395-1403, *Published Date 3/20/2006*
- 9481 Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of efficacy, quality of life, cost effectiveness and molecular markers
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RD, Naughton MJ, Weeks JC, Herndon JE, Zhang K, Mayer RJ
 Proc Gastrointestinal Cancers Symposium:183, 2005 *Published Date 1/27/2005*
- 9481 A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity
Mandola M, Stoehlmacher J, Muller-Weeks S, Cesarone G, Groshen S, Tsao-Wei D, Warren R, Lenz H, Ladner R
 Cancer Research 63(11):2898-2904, 2003 *Published Date 6/1/2003*
- 9481 Hepatic Arterial Infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer; a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz H-J, Naughton MJ, Weeks JC, Herndon JE, Zhang K, Mayer RJ
 Proc ASCO abstract #1010, 2003 *Published Date 5/31/2003*
- 9481 Thymidylate Synthase gene polymorphism determines thymidylate synthase mRNA levels and outcome of metastatic colorectal carcinoma treated with 5-Fluorouracil
Pullarkat ST, Xiong YP, Ghaderi V, Stoehlmacher J, Ingles SA, Sherrod A, Warren R, Wei DT, Groshen S, Lenz HJ
 Pharmacogenomics J 1 (1):65-70, 2001 *Published Date 5/1/2001*
- 9484 Breast cancer genetic studies in cooperative clinical cancer trials
McIntyre OR, Millikan RC, Dressler LG, Kornblith AB, Broadwater GJ, Sandler DP, Barcos MP, Collyar D
 DOD Breast Cancer Research Program, 1999 *Published Date 10/31/1999*
- 9484 Genetic testing in breast cancer cooperative clinical trials: Barriers and opportunities
Millikan RC, Kornblith AB, McIntyre OR, Berry DA, Broadwater GJ, Sandler DP, Karas KS, Dressler LG, Gross LS, Collyar D, Schilsky RL
 Cancer Therapeutics 1(2):96-100, 1998 *Published Date 6/3/1998*
- 9495 Induction chemoradiation and surgical resection for non-small cell lung carcinomas involving the superior sulcus: initial results of SWOG 9416 (Intergroup 0160/CALGB 9495)
Rusch VW, Giroux DJ, Kraut M, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck FC, Shepherd F, Burkes RL, Winton T, Deschamps C, Livingston R, Gandara D
 Journal of Thoracic and Cardiovascular Surgery 121(3):472-483, 2004 *Published Date 9/1/2004*
- 9495 Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of SWOG 9416/CALGB 9495/Intergroup 0160
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D
 J Thorac Cardiovasc Surg 121 (3):472-483, 2001 *Published Date 3/1/2001*

- 9497 Health status and quality of life in patients with early-stage Hodgkin's disease: a companion study to CALGB 9391/SWOG 9133
Ganz P, Moinpour CM, Pauler DK, Kornblith AB, Gaynor E, Balcerzak SP, Gatti GS, Erba H, McCoy S, Press O, Fisher R
Journal of Clinical Oncology 21(18):3512-3519, 2003 *Published Date 9/15/2003*
- 9498 A phase III intergroup (INT-0153) randomized trial of 5-FU/leucovorin/levamisole versus 5-FU continuous infusion levamisole for adjuvant treatment of stage III and high risk stage II colon cancer
Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, MacDonald JS
Journal of Clinical Oncology 23:1819-1825, 2005 *Published Date 3/20/2005*
- 9511 Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: CALGB 9511
Wetzler M, Sanford BL, Owzar K, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA
Blood 106(11):1825, 2005 *Published Date 11/15/2005*
- 9511 High levels of Wilm's tumor gene (WT1) expression is detected in the majority of newly diagnosed acute lymphoblastic leukemia of adults: implications for prognosis and monitoring of minimal residual disease: CALGB 9511
Stock W, Sher D, Dodge RK, Murciano E, Caligiuri M, Frankel S, Larson RA, Bloomfield CD
Blood 92(suppl 1):223a (#915), 1998 *Published Date 10/31/1998*
- 9511 Toxicity and pharmacokinetics of Peg-Asparaginase (PEG-asn) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511
Frankel SR, Kurtzberg J, DeOliveira D, Dodge RK, Peterson BL, Powell BL, Kolitz JE, Larson RA, Schiffer CA
Blood 90(Suppl 1):334a-1491, 1997 *Published Date 11/15/1997*
- 9511 Toxicity and pharmacokinetics of peg-asparaginase (peg-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511
Frankel SF, Kurtzberg J, DeOliveira D, Dodge R, Peterson B, Powell BL, Larson RA, Schiffer CA
Blood 88 (10): 669a, 1996 *Published Date 1/1/1996*
- 9530 Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
Kindler HL, Millard F, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR
Lung Cancer 31(2-3):311-317, 2001 *Published Date 1/5/2001*
- 9530 Gemcitabine for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9530)
Millard F, Herndon JE, Vogelzang NJ, Green MR
Proc ASCO 16:475a, 1997 *Published Date 5/1/1997*
- 9532 Paclitaxel/Ifosfamide or Navelbine/Ifosfamide Chemotherapy for Advanced Non-Small Cell Lung Cancer: CALGB 9532
Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR
Lung Cancer 28:63-68, 2000 *Published Date 6/1/1996*
- 9532 Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer; CALGB 9532
Perry MC, Ihde D, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR
Lung Cancer 28(1):63-68, 2000 *Published Date 4/1/2000*
- 9532 Paclitaxel/Ifosfamide chemotherapy for advanced non-small cell lung cancer; CALGB 9532
Perry MC, Ihde DC, Herndon JE, Box JW, Ijames ET, Green MR
Proc ASCO 17:470a-1809, 1998 *Published Date 5/15/1998*
- 9532 Paclitaxel/ifosfamide chemotherapy for advanced non-small cell lung cancer (NSCLC): CALGB 9532
Perry MC, Ihde DC, Herndon J, Atkins JN, Pillemer EA, Chahinian AP, R.Green M
Proc ASCO 16:478a-1721, 1997 *Published Date 5/15/1997*
- 9532 Vinorelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer (NSCLC): CALGB 9532
Ihde DC, Perry MC, Herndon JE, Atkins JN, Pillemer EA, Chahinian AP, Green MR
Proc ASCO 16:471a-1693, 1997 *Published Date 5/1/1997*

- 9534 Induction paclitaxel/carboplatin followed by concurrent chemoradiation for unresectable stage III non-small cell lung cancer: a limited-access study - CALGB 9534
Akerley W, Herndon JE, Lyss AP, Choy H, Turrisi AT, Graziano SL, Williams T, Zhang C, Vokes EE, Green MR
Clinical Lung Cancer 7(1):47-53, 2005 *Published Date 8/12/2005*
- 9534 Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial by the Cancer and Leukemia Group B.
Akerley WL, Herndon JE, Turrisi AT, Graziano S, Williams T, Sikov W, Choy H, Watson D, Green MR
Proc ASCO 19:490a-1915, 2000 *Published Date 5/20/2000*
- 9565 Pharmacokinetically-guided gemcitabine (dFdC) infusion scheduling to reduce potentially excessive plasma dFdC concentrations
Fisher JW, Florian JA, Parker RS, Venook AP, Ratain MJ, Egorin M
Proc ASCO:2025, 2005 *Published Date 5/16/2005*
- 9565 Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions
Fisher JW, Florian JA, Parker RS, Venook AP, Ratain MJ, Egorin M
Proc ASCO:2019, 2004 *Published Date 5/1/2004*
- 9565 A phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: CALGB 9565
Venook AP, Egorin M, Rosner GL, Hollis DR, Mani S, Hawkins MJ, Byrd JC, Hohl RJ, Budman DR, Meropol NJ, Ratain MJ
Journal of Clinical Oncology 18:2780-2787, 2000 *Published Date 7/1/2000*
- 9565 Phase I study of gemcitabine (G) in patients with organ dysfunction: CALGB 9565
Egorin M, Venook AP, Rosner GL, Hollis DR, Mani S, Hawkins MJ, Byrd JC, Hohl RJ, Budman DR, Poplin E, Meropol NJ, Ratain MJ
Proc ASCO 17:187a-719, 1998 *Published Date 5/15/1998*
- 9581 Phase III study of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)
Colacchio T, Niedzwiecki D, Compton CC, Warren R, Benson AI, Goldberg RM, Kerr D, Fields A, Hollis DR, Mayer RJ
Proc ASCO:3522, 2004 *Published Date 5/1/2004*
- 9583 Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: results from CALGB 9583
Ryan CJ, Halabi S, Small EJ, Hussain A, Philips GK, Kaplan EB, Vogelzang NJ
Proc ASCO:4558, 2004 *Published Date 5/1/2004*
- 9583 A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: results of CALGB 9583
Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable PS, Torti FM, Kaplan EB, Vogelzang NJ
Journal of Clinical Oncology 22:1025-1033, 2004 *Published Date 3/15/2004*
- 9583 Prognostic significance of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for Prostate Specific Antigen (PSA) in metastatic prostate cancer: A nested study within CALGB 9583
Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW
Journal of Clinical Oncology 21(3):490-495, 2003 *Published Date 6/1/2003*
- 9583 Prospective assessment of adrenal androgen levels as predictors of survival in androgen independent prostate cancer patients treated with ketoconazole
Vogelzang NJ, Halabi S, Picus J, Gable P, Hayes DF, Kantoff PW, Small EJ
Proc ASCO 20:749, 2001 *Published Date 5/1/2001*
- 9583 Reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) as a prognostic factor for survival among androgen independent prostate cancer patients (AiCaP)
Halabi S, Small EJ, Farmer D, Paradis A, Cen YY, Hayes DF, Vogelzang NJ, Kantoff PW
Proc ASCO 20:700, 2001 *Published Date 5/1/2001*

- 9583 A prospective randomized study of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients
Small EJ, Halabi S, Picus J, Cen YY, Vogelzang NJ
Proc ASCO 20:695, 2001 *Published Date 5/1/2001*
- 9590 Combined Etoposide, Ifosfamide, and Cisplatin in the Treatment of Patients with Advanced Thymoma and Thymic Carcinoma
Loehrer PJ, Jirutek M, Aisner S, Aisner J, Green M, Thomas CR, Livingston R, Johnson DH
Cancer 91:2010-2015, 2001 *Published Date 6/19/2001*
- 9592 Phase III trial of concurrent chemotherapy and radiotherapy vs CT/RT followed by surgical resection for stage IIIa(pN2) non-small cell lung cancer: outcomes and implications for surgical management in North American Intergroup 0139
Chen Y, Cox J, Darling G, Livingston R, Rusch V, Sause W, Shepherd F, Swann S, Turrisi AT, Albain K
Lung Cancer 49(suppl 2):S15, P-035, 2005 *Published Date 7/4/2005*
- 9596 Phase III study of PSC-833 in combination with vincristine, doxorubicin, and dexamethasone (PSC-833/VAD) versus VAD alone in patients with relapsing or refractory multiple myeloma (E1A95)
Friedenberg W, Rue M, Dalton W, Shustik C, Larson RA, Sonneveld P, Greipp P
Cancer 106(4):830-838, 2006 *Published Date 1/17/2006*
- 9620 Autologous stem cell transplantation for acute myeloid leukemia in second remission
Linker C, George S, Hurd D, Larson RA
Blood 98:689a (2881), 2001 *Published Date 11/1/2001*
- 9621 Overexpression of the ETS transcription factor ERG predicts a worse outcome in acute myeloid leukemia with normal karyotype: CALGB study 9621
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek KA, Whitman SP, Klisovic MI, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD
Journal of Clinical Oncology 23(36):9234-9242, 2005 *Published Date 12/20/2005*
- 9621 Independent validation of prognostic relevance of a previously reported gene-expression signature in acute myeloid leukemia with normal cytogenetics: a CALGB study
Marcucci G, Radmacher MD, Ruppert AS, Mrozek KA, Kolitz JE, Whitman SP, Edwards CG, Vardiman JW, Caligiuri MA, Carroll AJ, Larson RA, Bloomfield CD
Blood 106(11):755, 2005 *Published Date 11/15/2005*
- 9621 Overexpression of the ERG gene is an adverse prognostic factor in acute myeloid leukemia with normal cytogenetics: a CALGB study
Marcucci G, Baldus C, Ruppert AS, Radmacher MD, Mrozek KA, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Chapelle AD, Bloomfield CD
Blood 106(11):335, 2005 *Published Date 11/15/2005*
- 9621 Dose escalation studies of Cytarabine, Daunorubicin, and Etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with Acute Myeloid Leukemia <60 years old: Final induction results of CALGB Study 9621
Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Velez-Garcia E, Moore JO, Shea TC, Hoke EE, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA
Journal of Clinical Oncology 22(21):4290-4301, 2004 *Published Date 11/1/2004*
- 9621 Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): results from CALGB 9621
Kolitz JE, George SL, Barrier R, Hoke EE, Hurd DD, Velez-Garcia E, Powell BL, Marcucci G, Baer MR, Hohl RJ, Mrozek KA, Carroll AJ, Edwards CG, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA
Blood 102 (11):#612, 2003 *Published Date 11/16/2003*

- 9621 A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) < 60 years old with normal or unfavorable cytogenetics: results from CALGB 9621
Kolitz JE, George SL, Barrier R, Hoke EE, Hurd DD, Velez-Garcia E, Powell BL, Marcucci G, Brooks PL, Carroll AJ, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA
Blood 102 (11):#609, 2003 *Published Date 11/16/2003*
- 9621 Consolidation therapy by cytogenetic risk in adults with AML < 60 years in first complete remission
Kolitz JE, George SL, Dodge RK, Hoke E, Hurd DD, Powell BL, Velez-Garcia E, Caligiuri MA, Moore JO, Vardiman JW, Linker CA, Bloomfield CD, Larson RA
Blood 98:2879, 2001 *Published Date 11/1/2001*
- 9621 Dose escalation studies of Ara-C(A), Daunorubicin (D), and Etoposide (E) with and without multidrug resistance (MED) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) <60 years: final induction results
Kolitz JE, George SL, Dodge RK, Hoke E, Hurd DD, Powell BL, Velez-Garcia E, Caligiuri MA, Moore JO, Vardiman JW, Bloomfield CD, Larson RA
Blood 98:1928, 2001 *Published Date 11/1/2001*
- 9621 Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3
Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrozek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA
Cancer Research 61:7233-7239, 2001 *Published Date 10/1/2001*
- 9621 Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B Study
Mrózek KA, Prior TW, Edwards CG, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD
Journal of Clinical Oncology 19:2482-2492, 2001 *Published Date 7/4/2001*
- 9621 Morphology and CBFβ/MYH11 in AML (CALGB Study 9621)
Vardiman JW, Mrozek KA, Anastasi J, Hoke EE, Kolitz JE, Carroll AJ, Caligiuri MA, Marcucci G, Larson RA, Bloomfield CD
Lab Invest 80:165a #967, 2000 *Published Date 11/11/2000*
- 9621 Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with AML < 60 years, preliminary results of CALGB 9621
Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, Velez-Garcia E, Powell BL, Moore J, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA
Blood 93 (suppl 1):384a #1705, 1999 *Published Date 4/1/1999*
- 9621 Cytogenetic risk-adapted consolidation followed by immunotherapy with recombinant interleukin-2 (rIL-2) in patients < 60 years with AML in first complete remission (CR) preliminary results of CALGB 9621
Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, Caligiuri MA, Velez-Garcia E, Powell BL, Moore J, Vardiman JW, Bloomfield CD, Larson RA
Blood 93 (suppl 1):579a #2582, 1999 *Published Date 4/1/1999*
- 9621 A comparison of cytogenetic and molecular genetic detection of t(8;21)(q22;q22) and inv (16)(p13q22) in adults with de novo acute myeloid leukemia (AML): A Cancer and Leukemia Group B study
Mrozek KA, Prior TW, Edwards CG, Snyder PJ, Carroll AJ, Koduru PR, Pettenati MJ, Archer KJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD
Blood 92 (suppl 1):77a (#313), 1998 *Published Date 11/15/1998*
- 9631 High dose Doxorubicin, Dexrazoxane and GM-CSF in malignant mesothelioma: A phase II study CALGB 9631
Kosty MP, Herndon JE, Vogelzang NJ, Kindler HL, Green MR
Lung Cancer 34(2):289-295, 2001 *Published Date 4/25/2001*

- 9633 Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633
Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schilsky RL, Green MR
Proc ASCO:7019, 2004
Published Date 5/1/2004
- 9661 A phase I trial of escalating doses of trastuzumab combined with daily Subcutaneous Interleukin-2: report of Cancer and Leukemia Group B 9661
Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ
Clinical Cancer Research 8:3718-3727, 2002
Published Date 12/2/2002
- 9661 Phase I trial of recombinant human anti-Her2 monoclonal antibody (H) plus low-dose Interleukin-2 (IL-2) in solid tumors
Fleming G, Meropol NJ, Hollis DR, Rosner GL, Fracasso PM, Sosman JA, Tkaczuk L, Levine E, Rhoades CA, Caligiuri MA, Carson WE, Ratain MJ
Proc ASCO 18:184a-710, 1999
Published Date 5/15/1999
- 9663 Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration resistant prostate cancer - A CALGB study
Ross RW, Halabi S, Ou S, Rajeshkumar B, Woda B, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW
Clinical Cancer Research 11(22):8109-8113, 2005
Published Date 11/15/2005
- 9663 Androgen receptor mutations in androgen independent prostate cancer
Taplin ME, Rajeshkumar B, Halabi S, Woda B, Picus J, Hayes D, Kantoff P, Vogelzang NJ, Small EJ
Journal of Clinical Oncology 21(14):2673-2678, 2003
Published Date 7/15/2003
- 9663 Androgen receptor mutations in androgen independent prostate cancer (AIPCA) do not correlate with anti-androgen withdrawal response
Taplin ME, Halabi S, Rajeshkumar B, McQuain C, Woda BA, Picus J, Hayes DF, Vogelzang NJ, Small EJ
Proc ASCO 20:1738, 2001
Published Date 5/1/2001
- 9663 Androgen receptor analyses in androgen independent prostate cancer (AIPCA): Cancer and Leukemia Group B (CALGB) 9663.
Taplin M, Rajeshkumar B, Woda B, Halabi S, Prins GS, Picus J, Hayes DF, Vogelzang NJ, Small EJ
Proc ASCO 19:330a-1297, 2000
Published Date 5/20/2000
- 9665 Promoter methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia
Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C
Cancer Research 66(2):653-658, 2006
Published Date 1/15/2006
- 9665 Acute myeloid leukemia with deletion 9q is associated with CEBPA loss-of-function mutations
Frohling S, Schlenk RF, Krauter J, Thiede C, Haase D, Harder L, Kreitmeier S, Bloomfield CD, Caligiuri MA, Dohner H, Dohner K
Genes Chromosomes Cancer 42(4):427-432, 2005
Published Date 4/1/2005
- 9665 Global assessment of promoter methylation in a murine model of cancer identifies ID4 as a putative novel tumor suppressor gene in human leukemia
Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu Y, Raval A, Liu T, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd JC, Caligiuri MA, Plass C
Nature Genetics 37(3):265-274, 2005
Published Date 3/3/2005
- 9665 Global assessment of promoter methylation in a murine model of cancer identifies ID4 as a putative novel tumor suppressor gene in human leukemia
Yu Li, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Rval A, Liu TH, Dong W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd JC, Caligiuri MA, Plass C
Blood 104(11):3488, 2004
Published Date 12/1/2004
- 9665 Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia
Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Look AT
Blood 103(5):1919-1911, 2004
Published Date 3/1/2004

- 9665 BCR/ABL activates mdm2 mRNA translation via the La antigen
Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP, Caligiuri MA, Maraia RJ, Perrotti D, Calabretta B
Cancer Cell 3(2):145-60, 2003 *Published Date 2/1/2003*
- 9665 High affinity interleukin-3 receptor expression on blasts from patients with AML correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE
Leukemia Research 25(10):875-881, 2001 *Published Date 10/25/2001*
- 9665 Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci
Rush L, Dai Z, Smiraglia DJ, Gao X, Wright FA, Fruwald M, Costello JF, Held WA, Yu Li, Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C
Blood 97(10):3226-33, 2001 *Published Date 5/15/2001*
- 9665 Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics
Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, Chappelle Ad, Krahe R
Nature Genetics 27:65, 2001 *Published Date 4/1/2001*
- 9665 Gene expression profiling reveals fundamental biological differences in AML with isolated trisomy 8 and normal cytogenetics
Virtaneva KI, Wright FA, Tanner SM, Yuan Bo, Lemon WJ, Caligiuri MA, Bloomfield CD, Chappelle Ad, Krahe R
Proc Natl Acad Sci USA 98(3):1124-1129, 2001 *Published Date 1/30/2001*
- 9665 High affinity interleukin-3 receptor expression on blasts from patients with AML correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
Alexander RL, Ramage J, Klein B, Kucera GL, Caligiuri MA, Bloomfield CD, Frankel AE
Blood 96:304a, 2000 *Published Date 5/15/2000*
- 9665 DNA hypermethylation in AML: nonrandom patterns with preferential involvement of chromosome 11
Rush LJ, Gao X, Wright FA, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C
Blood 96:501a, 2000 *Published Date 5/15/2000*
- 9665 Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu Li, Bloomfield CD, Caligiuri MA, Plass C
Nature Genetics 25:132-138, 2000 *Published Date 2/15/2000*
- 9665 Aberrant DNA Methylation in AML
Rush L, Yu L, Bloomfield CD, Caligiuri MA, Plass C
Vet Pathol 36(5):488, 1999 *Published Date 11/16/1999*
- 9665 Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene.
Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, Caligiuri MA
Oncogene 18(20):3159-3165, 1999 *Published Date 11/11/1999*
- 9665 Gene expression in AML with trisomy 8
Tanner SM, Virtaneva K, Rush L, Caligiuri MA, Bloomfield CD, Plass C, Krahe R, Chappelle Ad
European J of Human Genetics 7 (suppl I):92 (P-300), 1999 *Published Date 11/11/1999*
- 9665 Novel genes in AML with trisomy 8
Tanner SM, Virtaneva K, Rush L, Caligiuri MA, Bloomfield CD, Plass C, Krahe R, Chappelle Ad
American Journal of Human Genetics 65 (4) Suppl A325:1834, 1999 *Published Date 11/11/1999*
- 9665 Gene expression pattern recognition for cancer classification
Golub T, Slonim D, Tamayo P, Huard C, Gasenbeek M, Mesirov J, Coller H, Loh M, Downing J, Caligiuri MA, Bloomfield CD, Lander E
Blood 94:656a, 1999 *Published Date 11/11/1999*
- 9665 Partial tandem duplication of MLL (MLL PTD): quantitative assessment of transcript copy number in AML with and without evidence of MLL gene rearrangement
Whitman SP, Strout MP, Maghraby EA, Marcucci G, Bloomfield CD, Caligiuri MA
Blood 94:53a, 1999 *Published Date 11/11/1999*

- 9665 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES
Science 286:531-537, 1999 *Published Date 10/15/1999*
- 9670 Barriers to clinical trial participation of older women with breast cancer
Kemeny MM, Muss HB, Kornblith AB, Peterson B, Wheeler J, Cohen HJ
Journal of Clinical Oncology 21(12):2268-2275, 2003 *Published Date 6/15/2003*
- 9670 Survey of oncologist's perceptions of barriers to accrual of older breast cancer patients to clinical trials
Kornblith AB, Kemeny MM, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss Hy, Cohen HJ
Cancer 95(5):989-996, 2002 *Published Date 9/1/2002*
- 9670 Barriers to participation of older women with breast cancer in clinical trials
Kemeny MM, Muss HB, Kornblith AB, Peterson B, Wheeler JD, Cohen HJ
Proc ASCO 19:602a-2371, 2000 *Published Date 5/20/2000*
- 9671 Long-term adjustment of survivors of early stage breast cancer treated by adjuvant chemotherapy twenty years ago: companion to CALGB 7581
Kornblith AB, Herndon JE, Weiss RB, Zuckerman EL, Rosenberg S, Mertz M, Zhang C, Payne D, Massie MJ, Holland JF, Bosl G, Byrd JC, Leone L, Norton L, Holland JC
Proc ASCO 20:1622, 2001 *Published Date 5/1/2001*
- 9680 Higher Doses of Mitoxantrone among men with Hormone Refractory Prostate Cancer: a Cancer and Leukemia Group B study
Levine E, Halabi S, Kaplan EB, Roberts JD, Rago R, Atkins JN, Vogelzang NJ
Cancer 94(3):665-672, 2002 *Published Date 2/1/2002*
- 9680 Preliminary results of CALGB 9680: A phase II trial of high dose mitoxantrone/GM-CSF and low dose steroids in hormone refractory prostate cancer (HRPC)
Levine E, Halabi S, Hars V, Rago R, Vogelzang NJ
Proc ASCO 17:336a-1297, 1998 *Published Date 5/15/1998*
- 9683 Phase II study of oral Eniluracil, 5-Fluorouracil, and Leucovorin in patients with advanced colorectal cancer
Meropol NJ, Niedzwiecki D, Hollis DR, Schilsky RL, Mayer RJ
Cancer 91(7):1256-1263, 2001 *Published Date 4/1/2001*
- 9687 Management of recurrent prostate cancer after radiotherapy: preliminary results of CALGB 9687, a contemporary salvage prostatectomy series
Sokoloff MH, Halabi S, Sanford BL, Eastham JA, Mohler JL, Walther PJ, Steinberg GD, Vogelzang NJ, Small EJ
ASCO Prostate Symposium:166, 2005 *Published Date 5/16/2005*
- 9712 Select high-risk genetic factors predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: preliminary justification for risk adapted therapy (CALGB 9712)
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA
Journal of Clinical Oncology 24(3):437-443, 2006 *Published Date 1/20/2006*
- 9712 Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: results from CALGB 9712
Byrd JC, Gribben JG, Peterson BL, Lozanski G, Lucas D, Smith L, Larson RA, Caligiuri MA, Heerema NA
Blood 104(11):476, 2004 *Published Date 12/1/2004*
- 9712 Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) study 9712
Morrison VA, Byrd JC, Peterson BL, Rai KR, Larson RA
Blood 102 (11):#1606, 2003 *Published Date 11/16/2003*

- 9712 Randomized phase II study of concurrent versus sequential treatment of rituximab with fludarabine in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: superior complete response rates with concurrent therapy: results of CALGB 9712
Byrd JC, Peterson BL, Morrison V, Park K, Jacobson R, Vardiman JW, Hoke E, Rai K, Schiffer CA, Larson RA
Blood 101(1):6-14, 2003 *Published Date 1/1/2003*
- 9712 Concurrent Rituximab and Fludarabine has a Higher Complete Response Rate than Sequential Treatment in Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Byrd JC, Peterson B, Park K, Morrison VA, Vardiman J, Jacobson R, Rai K, Larson RA
Blood 98(11):#3212, 2001 *Published Date 11/1/2001*
- 9712 Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia
Byrd JC, Peterson B, Park K, Morrison V, Vardiman JW, Jacobson RJ, Rai K, Larson RA
Proc ASCO 20:1116, 2001 *Published Date 5/1/2001*
- 9720 Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with AML: Cancer and Leukemia Group B study 9720
Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Calligiuri MA, Anastasi J, Powell Bl, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA
Blood 100:1224-1232, 2002 *Published Date 9/28/2002*
- 9720 Phase III study of PSC-833 modulation of multidrug resistance in previously untreated acute myeloid leukemia patients > 60 years (CALGB 9720)
Baer MR, George SL, Dodge RK, Cooke KD, Caligiuri MA, Powell BL, Kolitz JE, Larson RA
Blood 94:383a, 1999 *Published Date 11/1/1999*
- 9730 Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a randomized trial of efficacy, quality of life, and cost effectiveness
Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Weeks JC, Holland JC, Green MR
Journal of Clinical Oncology 23(1):190-196, 2005 *Published Date 1/1/2005*
- 9730 Single agent versus combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness: CALGB 9730
RC Lilenbaum, JE Herndon, List M, Desch C, Watson D, Holland J, Weeks J, MR Green
Proc ASCO 21:2, 2002 *Published Date 5/2/2002*
- 9730 Single agent versus combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness
Lilenbaum RC, Herndon J, List M, Desch C, Watson D, Holland JC, Weeks J, Green M
Proceedings at ECCO, 2001 *Published Date 6/30/2001*
- 9731 Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B
Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis DR, Ratain MJ, Green MR
Cancer 97(10):2480-2486, 2003 *Published Date 5/15/2003*
- 9731 CALGB 9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)
Akerley WL, Herndon JE, Egorin M, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen MD, Green MR
Proc ASCO 18:462a-1783, 1999 *Published Date 5/15/1999*

- 9732 A randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer: CALGB 9732
Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks R, Perry MC, Ansari RH, Otterson GA, Ellerton JA, Vokes EE, Green MR
 Journal of Clinical Oncology 23:3752-3759, 2005 *Published Date 6/1/2005*
- 9732 Randomized phase III intergroup trial of etoposide (VP-16) and cisplatin (DDP) +/- paclitaxel (Tax) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC): CALGB 9732
Niell HB, Herndon JE, Miller AA, Green MR
 Proc ASCO 21:1169, 2002 *Published Date 5/2/2002*
- 9733 Irinotecan for malignant mesothelioma: a phase II study
Kindler HL, Herndon JE, Zhang K, Green MR
 Lung Cancer 48(3):423-428, 2005 *Published Date 2/16/2005*
- 9733 CPT-11 in Malignant Mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733).
Kindler HL, Herndon JE, Vogelzang NJ, Green MR
 Proc ASCO 19:505a-1978, 2000 *Published Date 5/20/2000*
- 9734 Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/arboplatin) with or without radiation therapy for resected stage III non-small cell lung cancer
Perry MC, Kohman LJ, Bonner J, Gu L, Wang X, Vokes EE, Green MR
 Proc ASCO 7145:2005, 2005 *Published Date 5/15/2005*
- 9734 A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) with or without radiation therapy for resected stage III non-small cell lung cancer
Perry MC, Kohman LJ, Bonner JA, Zhang C, Herndon JE, Govindan R, Socinski MA, Vokes EE, Green MR
 Lung Cancer 41(S2):S55, 2003 *Published Date 8/1/2003*
- 9741 Dose-dense (DD) AC followed by paclitaxel is associated with mild, frequent anemia compared to sequential (S) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup trial C9741 with ECOG, SWOG, and NCCTG
Citron M, Berry DA, Cirrincione CT, Gradishar WJ, Livingston R, Perez EA, Muss HB, Norton L, Winer EP, Hudis CA
 Proc ASCO:620, 2005 *Published Date 5/16/2005*
- 9741 A randomized trial of dose dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: preliminary report of intergroup CALGB 9741
Citron MA, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Carpenter J, Hurd D, Holland JF, Smith B, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L
 Journal of Clinical Oncology 21(8):1431-1439, 2003 *Published Date 4/15/2003*
- 9741 Superiority of dose dense over conventionally scheduling and equivalence of sequential vs. combination adjuvant chemotherapy for node-positive breast cancer: CALGB 9741/Intergroup 9741
Citron M, Berry DA, Cirrincione C, Carpenter J, Hudis C, Gradishar W, Davidson N, Ingle J, Martino S, Livingston R, Winer E, Muss H, Norton L
 San Antonio Breast Cancer Symposium:15, 2002 *Published Date 12/10/2002*
- 9760 ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760)
Baer MR, Barrier R, Shoemaker JS, Cuvillo NW, O'Loughlin KL, Minderman H, Larson RA, Caligiuri MA
 Proc ASCO:6551, 2005 *Published Date 5/16/2005*

- 9761 Poor correspondence between clinical and pathologic staging in stage I non-small cell lung cancer: results from CALGB 9761, a prospective trial
D'Cunha J, Herndon JE, Herzan DL, Patterson GA, Kohman LJ, Harpole DH, Kernstine KH, Kern JA, Green MR, Maddaus MA, Kratzke RA
Lung Cancer 48(2):241-246, 2005 *Published Date 5/1/2005*
- 9761 Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B (CALGB) 9761
Vollmer RT, Herndon JE, D'Cunha J, Abraham NZ, Solberg J, Fatourechi M, Maruska A, Kratzke RA, Maddaus MA, Green MR, Kern JA
Clinical Cancer Research 9(15):5630-5635, 2003 *Published Date 11/15/2003*
- 9761 Poor correlation between clinical and pathological staging in stage I non-small cell lung cancer: results from CALGB 9761
D'Cunha J, Herndon JE, Herzan DL, Patterson A, Kohman L, Kern JA, Green MR, Maddaus MA, Kratzke RA
Proc ASCO abstract #2550, 2003 *Published Date 6/2/2003*
- 9761 Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B (CALGB) Trial 9761
Kratzke RA, Herndon JE, Vollmer RT, D'Cunha J, Abraham NZ, Maruska A, Kern JA, Green MR, Maddaus MA
Proc ASCO abstract #2552, 2003 *Published Date 5/31/2003*
- 9761 Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph-node micrometastatic tumor cell burden in Stage I Non-Small Cell Lung Cancer: Preliminary Results of Cancer and Leukemia Group B Trial 9761
D'Cunha J, Corfits AL, Herndon JE, Kern JA, Green MR, Kohman LJ, Patterson GA, Kratzke RA, Maddaus M
J Thorac Cardiovasc Surg 123(3):484-491, 2002 *Published Date 3/14/2002*
- 9762 Propective evaluation of the relationship of patient age and paclitaxel clinical pharmacology
Lichtman SM, Egorin M, Hollis DR, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd JC, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ
Journal of Clinical Oncology 24(12), 2006 *Published Date 4/20/2006*
- 9762 Clinical pharmacology of paclitaxel in relation to patient age
Lichtman SM, Egorin M, Rosner GL, Miller A, Rhoades C, Lester E, Hollis D, Rosen DM, Ratain MJ
Proc ASCO 20:265, 2001 *Published Date 5/1/2001*
- 9762 Clinical Pharmacology of Paclitaxel in Relation to Patient Age: CALGB 9762
Lichtman SM, Egorin M, Rosner GL, Miller AA, Rhoades CA, Hollis DR, Rosen DM, Ratain MJ
Proc ASCO 18:190a-732, 1999 *Published Date 5/15/1999*
- 9763 Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors
Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ
Clinical Cancer Research 10:8325-8331, 2004 *Published Date 12/30/2004*
- 9763 Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors
Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ
Proc ASCO abstract #500, 2003 *Published Date 5/31/2003*

- 9769 The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AS, Strout MP, Becknell B, Dorrance AM, Bruner R, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA
Blood 106(1):345-352, 2005 *Published Date 7/1/2005*
- 9769 Activation of the silenced MLL (ALL-1) wild-type allele in acute myeloid leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death
Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AS, Strout MP, Becknell B, Dorrance AM, Bruner R, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA
Blood 102 (11):#775, 2003 *Published Date 11/16/2003*
- 9780 A Phase II Study of Docetaxel, estramustine, and low dose hydrocortisone on the quality of life in men with hormone refractory prostate cancer and their partners: CALGB 9780
Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese DM, Holland JC, Vogelzang NJ
Annals of Oncology 12:633-641, 2001 *Published Date 5/15/2001*
- 9780 A phase II study of Docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: CALGB 9780
Savarese DM, Halabi S, Hars V, Akerley WL, Godley PA, Hussain A, Taplin ME, Small EJ, Vogelzang NJ
Journal of Clinical Oncology 19(9):2509-2516, 2001 *Published Date 5/1/2001*
- 9780 The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer [HRPC] and their partners.
Kornblith AB, Herndon JE, Zuckerman EL, Godley PA, Savarese DM, Vogelzang NJ, Holland JC
Proc ASCO 19:620a-2441, 2000 *Published Date 5/20/2000*
- 9780 A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: preliminary results of CALGB 9870
Savarese DM, Taplin M, Halabi S, Hars V, Kreis W, Vogelzang NJ
Seminars in Oncology 26:39, 1999 *Published Date 11/11/1999*
- 9780 A Phase II Study of Docetaxel, Estramustine, and Low Dose Hydrocortisone in Hormone Refractory Prostate Cancer: CALGB 9780
Savarese DM, Taplin M, Marchesani BJ, Kreis W, Akerley WL, Godley PA, Halabi S, Vogelzang NJ
Proc ASCO 18:321a-1234, 1999 *Published Date 5/15/1999*
- 9780 A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: preliminary results of CALGB 9780
Savarese DM, Taplin M, Marchesani BJ, Kreis W, Akerley WL, Godley PA, Halabi S, Vogelzang NJ
Journal of Urology 161(4):p296 #1137, 1999 *Published Date 4/1/1999*
- 9782 Efficacy of peripheral androgen blockade on prostate cancer: results of CALGB 9782
Picus J, Halabi S, Small EJ, Hussain A, Philips GK, Kaplan EB, Vogelzang NJ
Proc ASCO:4559, 2004 *Published Date 5/1/2004*
- 9782 Efficacy of peripheral androgen blockade on prostate cancer: initial results of CALGB 9782
Picus J, Halabi S, Dawson NA, Small EJ
Proc ASCO 21:727, 2002 *Published Date 5/2/2002*

- 9790 Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup trial (S9628)
Dhodapkar MV, Rasmussen E, Hussein M, Larson RA, Solomon A, Crowley J, Barlogie B
Blood 104(12):3520-3526, 2004 *Published Date 12/1/2004*
- 9793 Dose intensity of CHOP alone or with rituximab in diffuse large B-cell lymphoma in patients >60 years of age: an analysis of the intergroup trial (CALGB 9793/ECOG/SWOG 4494)
Morrison VA, Weller EA, Habermann TM, Li S, Gascoyne RD, Horning SJ, Fisher RI, Peterson BA
Annals of Oncology 16(s5):v102 #224, 2005 *Published Date 6/8/2005*
- 9793 Patterns of growth factor (GF) usage and febrile neutropenia (FN) among older patients with diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG/SWOG 4494)
Morrison VA, Weller EA, Habermann TM, Li S, Horning SJ, Fisher RI, Peterson BA
Blood 104(11):3309, 2004 *Published Date 12/1/2004*
- 9794 Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF-T with tamoxifen alone
Ravdin P, Green S, Albain K, Boucher V, Ingle JN, Pritchard K, Shepherd L, Davidson N, Hayes DF, Clark G, Martino S, Osborne CK, Allred DC
Proc ASCO 17:97a-374, 1998 *Published Date 5/15/1998*
- 9840 CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
Seidman AD, Berry DA, Cirrincione CT, Harris LN, Dressler LG, Muss HB, Naughton M, Norton L, Winer EP, Hudis CA
Proc ASCO:512, 2004 *Published Date 5/1/2004*
- 9862 High level of Wilms Tumor gene (WT1) expression is detected in the majority of newly diagnosed acute lymphoblastic leukemia (ALL) of adults: implications for prognosis and monitoring of minimal residual disease (MRD)
Stock W, Sher D, Dodge RK, Murciano E, Caligiuri MA, Frankel SR, Larson RA, Bloomfield CD
Blood 92(10) Suppl:#915, 1998 *Published Date 11/15/1998*
- 9863 A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
Venook AP, Klein CE, Fleming GF, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ
Annals of Oncology 14:1783-1790, 2003 *Published Date 12/3/2003*
- 9863 Phase I study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy
Venook AP, Klein C, Kastrissios H, Leichman CG, Hollis DR, Hohl RJ, Villalona-Calero MA, Aylesworth CA, Marshall JL, Budman DR, Rosner GL, Ratain MJ
Proc ASCO 20:293, 2001 *Published Date 5/1/2001*

- 9865 APC Promoter Hypermethylation Contributes to the Loss of APC Expression in Colorectal Cancers with Allelic Loss on 5q1
Arnold CN, Goel A, Niedzwiecki D, Dowell JM, Wasserman L, Compton CC, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Biology and Therapy 3(10):960-964, 2004 *Published Date 10/1/2004*
- 9865 Frequent inactivation of PTEN by promoter hypermethylation and its association with microsatellite instability-high (MSI-H) in sporadic colorectal cancers
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Research 64(9):3014-3021, 2004 *Published Date 4/1/2004*
- 9865 Epigenetic inactivation of RUNX3 is an important event in TGF- β mediated signaling in high-frequency microsatellite unstable (MSI-H) sporadic colon cancers
Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton CC, Mayer RJ, Bertagnolli MM, Boland CR
International Journal of Cancer 112:754-759, 2004 *Published Date 4/1/2004*
- 9865 Evaluation of microsatellite instability, HMLH1 expression and HMLH1 promoter hypermethylation in defining the phenotype of colorectal cancer: a study from CALGB 9865
Arnold CN, Goel A, Compton CC, Marcus V, Niedzwiecki D, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Biology and Therapy 3(1):73-78, 2004 *Published Date 1/5/2004*
- 9865 Characterization of sporadic colon cancer by patterns of genomic instability: results from CALGB 9865
Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Research 63(7):1608-1614, 2003 *Published Date 4/1/2003*
- 9865 RUNX3: a novel tumor suppressor gene frequently silenced by promoter hypermethylation in sporadic colon cancers: results from CALGB 9865
Goel A, Fiorino A, Arnold CN, Tassone P, Niedzwiecki D, Wasserman L, Compton CC, Mayer RJ, Bertagnolli MM, Boland CR
Proc DDW online abstract ID:102989, 2003 *Published Date 4/1/2003*
- 9865 Evaluation of Microsatellite Instability, hMLH1 Expression and hMLH1 Promoter Hypermethylation in Defining the Phenotype of Colorectal Cancer: a Study from CALGB 9865
Arnold CN, Goel A, Compton CC, Marcus V, Niedzwiecki D, Wasserman L, Mayer RJ, Bertagnolli MM, Boland CR
Proc DDW online abstract ID:100611, 2003 *Published Date 4/1/2003*
- 9865 Frequent inactivation of PTEN by Promoter Methylation in the Microsatellite-High (MSI-H) sporadic colorectal cancers
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Gastroenterology 122(5A):S899, 2002 *Published Date 6/1/2002*
- 9865 Tumor suppressor genes are a 'target' of Promoter Hypermethylation in MSI-H sporadic colorectal cancers: New insights into the mechanism of colon carcinogenesis
Goel A, Arnold CN, Chang DK, Niedzwiecki D, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Gastroenterology 122(5A):133, 2002 *Published Date 6/1/2002*
- 9865 Promoter Hypermethylation plays a principal role in colon carcinogenesis in chromosomally and microsatellite stable tumors
Inoue T, Goel A, Arnold CN, Niedzwiecki D, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Gastroenterology 122(5A):M906, 2002 *Published Date 6/1/2002*
- 9865 APC Promoter Hypermethylation contributes strongly to loss of APC expression in colorectal cancers with allelic loss on 5q
Arnold CN, Goel A, Compton C, Niedzwiecki D, Mayer RJ, Bertagnolli MM, Boland CR
Gastroenterology 122(5A):S886, 2002 *Published Date 6/1/2002*
- 9865 Microsatellite-High (MSI-H) tumors are not associated with LOH at the APC locus compared to microsatellite-Low/Stable (MSI-L/MSS) tumors
Arnold CN, Goel A, Chang DK, Wasserman L, Compton C, Niedzwiecki D, Mayer R, Bertagnolli MM, Boland CR
Gastroenterology 120(5A):296, 2001 *Published Date 4/1/2001*
- 9865 Chromosomal vs microsatellite instability in colorectal cancers: Evidence for previously unrecognized pathways
Goel A, Arnold CN, Chang DK, Ricciardiello L, Chauhan DP, Carethers JM, Wasserman L, Bertagnolli MM, Boland CR
Gastroenterology 120(5A):163, 2001 *Published Date 4/1/2001*
- 9865 Somatic frameshift mutations in MBD4 (MED1) are not exclusively associated with microsatellite high (MSI-H) colorectal tumors
Goel A, Arnold CN, Ricciardiello L, Chang DK, Wasserman L, Compton C, Niedzwiecki D, Mayer R, Bertagnolli MM, Boland CR
Gastroenterology 120(5A):293, 2001 *Published Date 4/1/2001*

- 9865 A panel of mono and di nucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer
Arnold CN, Goel A, Carethers J, Wasserman L, Compton C, Niedzwiecki D, Mayer R, Bertagnolli MM, Boland CR
Gastroenterology 120(5A):599, 2001 *Published Date 4/1/2001*
- 9871 The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in caucasian and African American patients with solid tumors:CALGB 9871
Lewis LD, Rosner GL, Miller AA, Egorin M, Relling MV, Kastrissios H, Bies R, Ratain MJ
Proc ASCO:2043, 2004 *Published Date 5/1/2004*
- 9872 Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women on adjuvant tamoxifen
Garber JE, Halabi S, Kaplan EB, Edge S, Dressler LG, Paskett ED, Berliner N
Proc ASCO:508, 2005 *Published Date 5/16/2005*
- 10102 Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia: a phase I/II study from CALGB
Stock W, Yu D, Sanford BL, Lozanski G, Cataland SR, Vij R, Byrd JC, Powell BL, Wetzler M, Albitar M, Sher DA, Edwards CG, Hoke EE, Bloomfield CD, Larson RA
Blood 106(11):145, 2005 *Published Date 11/15/2005*
- 10103 Fludarabine and cyclophosphamide produce a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: intergroup trial E2997
Flinn IW, Kumm E, Grever MR, Neuberg D, Dewald GW, Bennett JM, Palette EM, Hussein MA, Moore DF, Tallman M
Blood 104(11):475, 2004 *Published Date 12/1/2004*
- 10103 Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia is adversely impacted by high risk genetic features: results from intergroup E2997
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Flinn IW, Tallman M, Gribben JG, Byrd JC
Blood 104(11):3487, 2004 *Published Date 12/1/2004*
- 10104 Differences in prognostic factors and outcomes in African-Americans and Caucasians with Acute Myeloid Leukemia
Sekeres M, Peterson BL, Dodge RK, Mayer RJ, Moore JO, Lee E, Kolitz JE, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM
Blood 103(11):4036-4042, 2004 *Published Date 6/1/2004*
- 10104 Racial differences in prognostic factors and outcome in acute myeloid leukemia, CALGB 10104
Sekeres MA, Dodge RK, Bloomfield CD, Larson RA, Stone RM
Blood 100 (suppl 1):323, 2002 *Published Date 12/20/2002*
- 10107 Feasibility of administering oblimersen (G3139: Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia: CALGB 10107
Wetzler M, Yu D, Odenike OM, Feldman EJ, Hurd DD, Hoke EE, Hars V, Larson RA
Blood 106(11):1097, 2005 *Published Date 11/15/2005*

- 10301 Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301
Orlowski RZ, Peterson BL, Caligiuri MA, Kelly M, Larson RA
Haematologica 90(s1):PO.730, 2005 *Published Date 4/1/2005*
- 19801 Phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL)
DeAngelo DJ, Yu D, Dodge RK, Coutre SE, Mitchell BS, Stone RM, Stopeck AT, Larson RA
Blood 100 (suppl 1):743, 2002 *Published Date 12/20/2002*
- 19802 Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia: final analysis of CALGB 19802
Stock W, Johnson JL, Yu D, Bennett D, Sher DA, Stone RM, Kolitz JE, Powell BL, Wetzler M, Vardiman JW, Bloomfield CD, Larson RA
Blood 106(11):1833, 2005 *Published Date 11/15/2005*
- 19802 Intensified daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): results of CALGB 19802
Stock W, Yu D, Johnson JL, Bloomfield CD, Stone RM, Kolitz JE, Wetzler M, Powell BL, Vardiman JW, Larson RA
Blood 102 (11):#1375, 2003 *Published Date 11/16/2003*
- 19802 Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Phase II Trial of Dose Intensification of Daunorubicin and Cytarabine Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradiation
Stock W, Dodge RK, Vardiman JW, Bloomfield CD, Caligiuri MA, Frankel SR, Stone RM, Larson RA
Blood 98:2472, 2001 *Published Date 11/1/2001*
- 19803 Relationships of response to oral topotecan for myelodysplastic syndrome with IPSS group and cytogenetics
Grinblatt DL, Yu D, Hars V, Miller AA, Carroll A, Powell BL, Bloomfield CD, Larson RA
Blood 100(suppl 1):3137, 2002 *Published Date 12/20/2002*
- 19803 Oral topotecan for myelodysplastic syndrome (MDS) 2 schedules
Grinblatt DL, Yu D, Hars V, Kastrissios H, Miller AA, Larson RA
Proc ASCO 20:1209, 2001 *Published Date 5/1/2001*
- 19804 A phase II study of homoharringtonine in combination with low-dose cytarabine via continuous IV infusion for newly diagnosed patients with chronic myeloid leukemia: CALGB 19804
Stone RM, Yu D, Stock W, Hars V, Linker C, DeAngelo D, Shea T, Marcucci G, Larson RA
Blood 100 (suppl 1):3101, 2002 *Published Date 12/20/2002*
- 19805 Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or one-hour bolus infusion: results from CALGB 19805
Byrd JC, Peterson BL, Gabilove JL, Odenike OM, Grever MR, Rai KR, Larson RA
Clinical Cancer Research 11(11):4176-4181, 2005 *Published Date 6/1/2005*
- 19805 Sequential phase II studies of flavopiridol by 72-hour continuous infusion and one-hour intravenous bolus for the treatment of relapsed B-cell chronic lymphocytic leukemia: results from CALGB 19805
Byrd JC, Peterson BL, Gabilove JL, Odenike O, Grever M, Rai KR, Vardiman JW, Larson RA
Blood 104(11):3485, 2004 *Published Date 12/1/2004*

- 19808 A randomized comparison of induction therapy for untreated acute myeloid leukemia in patients < 60 years using P-glycoprotein modulation with valsopodar: preliminary results of CALGB 19808
Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Hars V, Hoke EE, Vardiman JW, Bloomfield CD, Larson RA
Blood 106(11):407, 2005 *Published Date 11/15/2005*
- 19901 Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901
Rai KR, Byrd JC, Peterson BL, Gautier M, Larson RA
Blood 102 (11):#2506, 2003 *Published Date 11/16/2003*
- 19901 A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease
Rai KR, Byrd JC, Peterson BL, Larson RA
Blood 100 (suppl 1):772, 2002 *Published Date 12/20/2002*
- 19902 A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902
Stone RM, Moser BK, Schulman PP, Barrier R, Kolitz JE, Allen SL, Stock W, Galinsky IA, Khoury H, Larson RA
Blood 104(11):873, 2004 *Published Date 12/1/2004*
- 29801 Blood and bone marrow are equivalent for real time RT-PCR monitoring of BCR/ABL transcripts in patients receiving treatment for Chronic Myelogenous Leukemia: A Cancer and Leukemia Group B Study (CALGB 29801)

Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD
International Journal of Oncology, *Accepted Date 12/2/2005*
- 30002 Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002
Miller AA, Bogart JA, Wang X, Lima CM, Vokes EE, Green MR
Proc ASCO:7170, 2005 *Published Date 5/16/2005*
- 30004 Phase II trial of karenitecin in patients with relapsed or refractory non small cell lung cancer: CALGB 30004
Miller AA, Herndon JE, Gu L, Green MR
Lung Cancer 48(3):399-407, 2005 *Published Date 5/11/2005*
- 30004 Phase II trial of karenitecin (IND 57250) in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004
Zhang K, Miller AA, Herndon JN, Green MR
Proc ASCO abstract #2706, 2003 *Published Date 5/31/2003*
- 30101 Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B (CALGB 30101)
Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer RT, Watson DM, Green MR, Kindler HL
Clinical Cancer Research 11(6):2300-2304, 2005 *Published Date 3/15/2005*
- 30101 Gefitinib in Patients with Malignant Mesothelioma (MM): A Phase II Study by the Cancer and Leukemia Group B (CALGB 30101)
Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL
Proc ASCO abstract #2535, 2003 *Published Date 5/31/2003*

- 30103 A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC) CALGB 30103
Rudin CM, Salgia R, Wang X, Vokes EE, Green MR
Proc ASCO:7168, 2005 *Published Date 5/16/2005*
- 30104 A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104
Wang X, Govindan R, Herndon JE, Watson DM, Florence R, Vokes EE, Green MR
Proc ASCO:7161, 2005 *Published Date 5/16/2005*
- 30105 Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a Cancer and Leukemia Group B (CALGB 30105) randomized phase II trial
Blackstock AW, Socinski MA, Rosenman J, Gu L, Wang X, Bogart JA, Vokes EE, Green MR
Proc ASCO:7060, 2005 *Published Date 5/16/2005*
- 30106 Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): a CALGB stratified phase II trial
Ready N, Herndon JE, Vokes EE, Bogart JA, Crawford J, DiPetrillo T, Green MR
Proc ASCO:7078, 2004 *Published Date 5/1/2004*
- 30107 Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)
Jahan TM, Gu L, Wang X, Kratzke RA, Green MR, Vokes EE, Kindler HL
Lung Cancer 49(suppl 2):S222, P-403, 2005 *Published Date 7/4/2005*
- 30201 A phase II NCCTG/CALGB trial of imatinib (STI571) in patients with c-kit expressing relapsed small cell lung cancer: N0124/C30201
Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Morton RF, Schild SE, Jett JR, Adjei A
Annals of Oncology 16:1811-1816, 2005 *Published Date 11/15/2005*
- 30201 A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit expressing relapsed small cell lung cancer: N0124/C30201
Adjei A, Mandrekar S, Dy GK, Bot B, Miller AA
Proc ASCO:7048, 2005 *Published Date 5/16/2005*
- 39801 Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial
Vokes EE, Herndon JE, Kelley MJ, Watson DM, Cicchetti MG, Green MR
Proc ASCO:7005, 2004 *Published Date 5/15/2004*
- 39801 A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC)
Tothy PK, Mauer AM, Haraf D, Rudin CM, Hoffman PC, Ferguson MK, Szeto L, Vokes EE
Proc ASCO:7170, 2004 *Published Date 5/1/2004*

- 39802 Feasibility of video-assisted thoracic surgery(VATS) lobectomy for early stage lung cancer: Results of CALGB 39802
Swanson S, Herndon J, D'Amico A, Demmy T, McKenna R, Green M, Sugarbaker D
Proc ASCO 21:1158, 2002 *Published Date 4/15/2002*
- 39803 Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): results of CALGB 39803
Jaklitsch MT, Gu L, Harpole DH, D'Amico TA, McKenna RJ, Krasna MJ, Kohman LJ, Swanson SJ, DeCamp MM, Sugarbaker DJ
Proc ASCO:7065, 2005 *Published Date 5/16/2005*
- 39805 A phase II trial of 6-hydroxymethylacyfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer
Sherman CA, Herndon JE, Watson DM, Green MR
Lung Cancer 45(3):387-392, 2004 *Published Date 9/23/2004*
- 39807 Capecitabine (xeloda) in malignant mesothelioma: a phase II trial by the CALGB
Otterson GA, Herndon JE, Watson D, Green MR, Kindler HL
Lung Cancer 44(2):251-259, 2004 *Published Date 5/1/2004*
- 39807 Capecitabine (Xeloda) in malignant mesothelioma: a phase II trial by the CALGB
Otterson GA, Herndon JE, Watson D, Terrenoire J, Green MR, Kindler HL
Proc ASCO abstract #2778, 2003 *Published Date 5/31/2003*
- 39808 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for for limited stage small cell lung cancer (L-SCLC): preliminary analysis of CALGB 39808
Bogart JA, Herndon JE, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR
Int'l Jnl Rad Onc, Biol & Phys 59(2):460-468, 2004 *Published Date 6/1/2004*
- 39808 70 Gy Thoracic Radiotherapy (TRT) concurrent with Cycle 3 of chemotherapy is feasible for Limited Stage Small Cell Lung Cancer (L-SCLC): Preliminary analysis of CALGB 39808
Bogart JA, Herndon JE, Lyss AP, Watson D, Crawford J, Miller A, Turisi A, Green MR
International Journal of Radiation Oncology*Biolog*Physics 54(2):103, 2002 *Published Date 5/2/2002*
- 39808 Spinal cord dose in limited stage small cell lung cancer: a preliminary quality assurance review committee (QARC) report on CALGB 39808 using target thoracic radiotherapy (TRT) doses of 60-70 Gy
Cicchetti MG, Bogart JA, Lyss AP, Turrisi AT, Green M, Herndon JE
Int J Radiat Oncol Biol Phys 51(3):356, 2001 *Published Date 11/1/2001*
- 39808 Phase II study of Topotecan (Topo) + paclitaxel (tax) + G-CSF induction followed by concurrent chemoradiotherapy (CCRT) for patients (pts) with limited stage small cell lung cancer (L-SCLC): Preliminary analysis for CALGB 39808
Lyss AP, Herndon JE, Bogart JA, Watson DM, Turrisi AT, Green MR
Proc ASCO 20:1270, 2001 *Published Date 5/1/2001*
- 39809 Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
Rocha-Lima CM, Rizvi NA, Zhang K, Herndon JE, Garst JL, Govindan R, King G, Green MR
Annals of Oncology 15:410-418, 2004 *Published Date 3/30/2004*
- 39809 Randomized Phase II Trial of Gemcitabine/Irinotecan and Gemcitabine/Docetaxel in Stage IIIB (Malignant Pleural Effusion) or Stage IV NSCLC: CALGB 39809
Lima CM, Lee H, Rizvi NA, Herndon JE, Zhang K, Crawford J, King GW, Green MR
Proc ASCO 21:1344, 2002 *Published Date 4/24/2003*

- 39810 Lack of trastuzumab activity in non-small cell lung cancer over-expressing erb-B2: 39810 a phase II trial of CALGB
Clamon GH, Garst JL, Govindan R, Green MR, Herndon JE, Kern JA, Watson DM
 Cancer 103(8):1670-1675, 2005 *Published Date 4/15/2005*
- 39901 Dose-dense weekly paclitaxel in extensive stage small-cell lung cancer: CALGB 39901
Graziano S, Socinski MA, Herndon JE, Watson D, Green MR
 Proc ASCO abstract #2598, 2003 *Published Date 5/31/2003*
- 49805 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
Gross PE, Ingle JN, Martino S, Robert N, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston R, Davidson N, Norton L, Perez EA, Abrams J, Therasse P, Palmer MJ, Pater J
 The New England Journal of Medicine 349(19):1793-1802, 2003 *Published Date 11/6/2003*
- 50002 Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL): CALGB study 50002
Grinblatt DL, Johnson JL, Niedzwiecki D, Rizzieri DA, Bartlett NL, Cheson BD
 Blood 104(11):3284, 2004 *Published Date 12/1/2004*
- 50103 Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103
Wilson WH, Niedzwiecki D, Zelenetz AD, Hurd DD, Porcu P, Martin E, Czuczman MS, Cheson BD, Canellos GP
 Proc ASCO:6530, 2005 *Published Date 5/16/2005*
- 59804 A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: preliminary results of CALGB 59804
Bartlett N, Niedzwiecki D, Johnson J, Friedberg JW, Zelenetz AD, Canellos GP
 Proc ASCO abstract #2275, 2003 *Published Date 5/31/2003*
- 59901 CALGB 59901: results of a phase II study of 506U78 in CTCL and PTCL
Czuczman MS, Porcu P, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD
 Blood 104(11):2486, 2004 *Published Date 12/1/2004*
- 59902 A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) results of E1496
Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR, Horning SJ
 Proc ASCO:6502, 2004 *Published Date 5/1/2004*
- 59902 Increased mortality associated with the cyclophosphamide 1000 mg/m² & Fludarabine 20 mg/m² qd x 5 (CF) arm in patients with low grade lymphoma treated on E1496/CALGB 59902
Hochster H, Weller E, Kunzel T, Canellos G, Gray R, Horning S
 Proc ASCO 21:1125, 2002 *Published Date 5/2/2002*

- 59906 Sequential doxorubicin and topotecan in relapsed/refractory aggressive NHL: results of CALGB 59906
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos GP, Cheson BD, Bartlett NL
 Leukemia and Lymphoma, *Accepted Date 1/13/2006*
- 59906 Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: results of CALGB 59906, a phase II study of doxorubicin and topotecan
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos GP, Cheson BD, Bartlett NL
 Blood 104(11):2500, 2004 *Published Date 12/1/2004*
- 59909 Eradication of minimal residual disease during treatment of mantle cell lymphoma: CALGB 59909
Sher DA, Johnson JL, Siddiqui M, Damon L, Linker C, Cheson BD, Stock W
 Blood 104(11):1652, 2004 *Published Date 12/1/2004*
- 59909 Intense immunochemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients with mantle cell lymphoma (MCL): CALGB 59909
Damon L, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Kelly M, Linker C, Canellos GP
 Blood 104(11):895, 2004 *Published Date 12/1/2004*
- 69901 Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole (CAI) in renal cell carcinoma (CALGB 69901)
Stadler WM, Rosner GL, Small EJ, Hollis DR, Rini BI, Zaentz D, Mahoney JF, Ratain MJ
 Journal of Clinical Oncology 23(16):3726-3732, 2005 *Published Date 6/1/2005*
- 69901 Successful implementation of the randomized discontinuation trial design to assess disease stabilization in renal cell carcinoma patients treated with the putative antiangiogenic agent carboxyaminoimidazole: A CALGB study
Stadler WM, Rosner G, Rini B, Hollis D, Small EJ, Ratain MJ
 Proc ASCO abstract #773, 2003 *Published Date 5/31/2003*
- 69901 Randomized discontinuation design: application to cytostatic antineoplastic agents
Rosner G, Stadler W, Ratain MJ
 Journal of Clinical Oncology 20 (22):4478-4484, 2002 *Published Date 11/15/2002*
- 79804 Economic outcomes of breast cancer survivorship: CALGB 79804
Hensley ML, Dowell J, Herndon JE, Winer E, Stark N, Weeks JC, Paskett E
 Breast Cancer Research and Treatment 91(2):153-161, 2005 *Published Date 5/15/2005*
- 80001 Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of CALGB 80001
Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JW, Bem J, Mayer RJ, Bertagnolli MM
 Journal of Clinical Oncology 24(6):878-883, 2006 *Published Date 1/15/2006*
- 80001 Sentinel node staging of resectable colon cancer: results of CALGB 80001 a multicenter study
Bertagnolli MM, Miedema BW, Redston M, Dowell JM, Niedzwiecki D, Fleshman JW, Bem J, Mayer RJ, Zinner MJ, Compton CC
 Annals of Surgery 240(4):624-628, 2004 *Published Date 11/28/2004*
- 80001 Sentinel node staging of resectable colon cancer: results of CALGB 80001
Bertagnolli MM, Redston M, Miedema BW, Dowell JM, Niedzwiecki D, Mayer RJ, Fleshman J, Bem J, Compton CC
 Proc ASCO:3506, 2004 *Published Date 5/1/2004*

- 80003 A phase II trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced non-metastatic pancreatic adenocarcinoma: preliminary analysis of CALGB 80003
Mamon H, Niedzwiecki D, Hollis DR, Tan BR, Smith JL, Blackstock AW, Tepper JE, Goldberg RM, Mayer RJ, Fuchs CS
International Journal of Radiation Oncology, Biology, Physics 63 suppl:S13, 2005 *Published Date 12/1/2005*
- 80004 Phase III dose-randomized study of imatinib meysylate (Gleevec, STI571) for GIST: intergroup S0033 (CALGB 80004) early results
Demetri GD, Rankin C, Fletcher C, Benjamin RS, Blanke C, Mehren MV, Bramwell V, Maki RG, Blum R, Antman K, Baker L, Borden E
Proc ASCO 21:1651, 2002 *Published Date 5/1/2002*
- 80405 A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland SL, Goldberg RM
Clinical Colorectal Cancer 5:292-294, 2005 *Published Date 12/25/2005*
- 89803 Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803
Fuchs CS, Meyerhardt JA, Brady DL, Niedzwiecki D, Hollis DR, Chan AT, Saltz LB, Schilsky RL, Mayer RJ
Proc ASCO:3530, 2005 *Published Date 5/16/2005*
- 89803 The impact of physical activity on patients with stage III colon cancer: findings from intergroup trial CALGB 89803
Meyerhardt JA, Brady DL, Niedzwiecki D, Hollis DR, Saltz LB, Willett WC, Mayer RJ, Schilsky RL, Fuchs CS
Proc ASCO:3534, 2005 *Published Date 5/16/2005*
- 89803 Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial/CALGB 89803)
Saltz LB, Niedzwiecki D, Hollis DR, Goldberg RM, Hantel A, Thomas JP, Fields AL, Carver G, Mayer RJ
Proc ASCO:3500, 2004 *Published Date 5/1/2004*
- 89804 Cost-effectiveness projections of FOLFOX vs IFL in first-line therapy of metastatic colorectal cancer
Hillner BE, Schrag D, Sargent DJ, Morton R, Fuchs CS, Goldberg RM
Cancer 104:1871-1884, 2005 *Published Date 9/21/2005*
- 89804 A pooled analysis to assess safety and efficacy of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly patients with colorectal cancer
Sargent D, Goldberg RM, Bleiberg H, deGramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Mounedji-Boudiaf L, Tabah-Fisch I
7th World Congress on Gastrointestinal Cancer, 2005 *Published Date 6/15/2005*
- 89804 Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
Meyerhardt JA, Sloan JA, Zhao X, Pollak M, Sargent DJ, Goldberg RM, Fuchs CS
Cancer Epidemiology, Biomarkers & Prevention 14(6):1402-1410, 2005 *Published Date 6/14/2005*
- 89804 Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity
Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson S, Findlay B, Goldberg RM
ASCO 23:248s#3509, 2005 *Published Date 5/16/2005*
- 89804 Cost effectiveness projections of FOLFOX vs IFL in first-line therapy of metastatic colorectal cancer in the context of the US healthcare system
Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM
ASCO 23:253s, 2005 *Published Date 5/16/2005*
- 89804 A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer
Morton RF, Sloan JA, Grothey A, Sargent DJ, McLeod HL, Green EM, Fuchs CS, Ramanathan RK, Williamson SK, Goldberg RM
ASCO 23:750s, 2005 *Published Date 5/16/2005*

- 89804 Chemotherapy permits resection of metastatic colorectal cancer: experience from intergroup N9741
Delaunoit T, Krook J, Sargent DJ, Green E, Alberts SR, Fuchs CS
Annals of Oncology 16(3):425-429, 2005 *Published Date 3/3/2005*
- 89804 Detailed analysis of oxaliplatin-associated neurotoxicity in intergroup trial N9741
Green EM, Sargent DJ, Goldberg RM, Grothey A
Proc Gastrointestinal Cancers Symposium:182, 2005 *Published Date 1/27/2005*
- 89804 Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from intergroup N9741
Dy GK, Krook J, Green EM, Sargent DJ, Alberts S, Pitot H, Morton R, Goldberg RM
Proc Gastrointestinal Cancers Symposium:185, 2005 *Published Date 1/27/2005*
- 89804 Cost-effectiveness projections of FOLFOX vs IFL in first-line therapy of metastatic colorectal cancer
Hillner BE, Schrag D, Sargent DJ, Goldberg RM
Proc Gastrointestinal Cancers Symposium:187, 2005 *Published Date 1/27/2005*
- 89804 Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): results from intergroup trial N9741
Fuchs CS, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM
Proc ASCO:3521, 2004 *Published Date 5/1/2004*
- 89804 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR
Journal of Clinical Oncology 22(1):23-30, 2004 *Published Date 4/1/2004*
- 89804 Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741
Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA
Cancer 101(10):2170-2176, 2004 *Published Date 4/1/2004*
- 89804 Oxaliplatin or CPT-11 + 5-fluorouracil/leucovorin or oxal + CPT-11 in advanced colorectal cancer: initial toxicity and response data from GI intergroup study N9741 (CALGB 89804)
Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP
Proc ASCO 21:511, 2002 *Published Date 5/1/2002*
- 89805 Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
International Journal of Gastrointestinal Cancer 34(2/3):107-116, 2004 *Published Date 4/1/2004*
- 89805 Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
International Journal of Radiation Oncology*Biophysics*Physics 51(3):31, 2001 *Published Date 11/1/2001*
- 89805 Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
Proc ASCO 20:627, 2001 *Published Date 5/1/2001*
- 89901 A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901
Ryan DP, Niedzwiecki D, Hollis DR, Miedema BW, Wadler S, Tepper JE, Mayer RJ
Proc ASCO:3560, 2004 *Published Date 5/1/2004*

- 89902 Phase II trial of 5-fluorouracil, leucovorin, oxaliplatin and herceptin for patients with metastatic colorectal cancer refractory to initial therapy
Clark JW
Proc ASCO abstract #3584, 2003 *Published Date 5/31/2003*
- 89904 A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904)
Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ
Proc ASCO:4011, 2004 *Published Date 5/1/2004*
- 90003 CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: an intergroup phase II study
Rini BI, Halabi S, Barrier R, Margolin K, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker C, Small EJ
Biology of Blood and Marrow Transplantation, *Accepted Date 3/29/2006*
- 90003 CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: an intergroup phase II study
Rini BI, Halabi S, Barrier R, Margolin K, Avigan D, Logan T, Small EJ, Linker C
Blood 104(11):810, 2004 *Published Date 12/1/2004*
- 90004 A phase II Study of estramustine (E), docetaxel (D) and exisulind in hormone-refractory prostate cancer (HRPC): initial results of CALGB 90004
Dawson NA, Halabi S, Biggs DD, Ou S, Kelly WK, Small EJ
Proc ASCO:4649, 2005 *Published Date 5/16/2005*
- 90006 The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006
Picus J, Halabi S, Vogelzang NJ, Kaplan EB, Kelly W, Small EJ
Proc ASCO abstract #1578, 2003 *Published Date 5/31/2003*
- 90008 A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B 90008
Stadler WM, Halabi S, Ernstoff MS, Barrier R, Davila E, Picus J, Small EJ
Proc ASCO:4515, 2004 *Published Date 5/1/2004*
- 90102 Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: results of CALGB 90102
Philips GK, Halabi S, Sanford BL, Bajorin DF, Small EJ
Proc ASCO:4540, 2004 *Published Date 5/1/2004*
- 90206 CALGB 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-VEGF antibody (bevacizumab, Avastin®) in metastatic renal cell carcinoma
Rini BI, Halabi S, Taylor JR, Small EJ, Schilsky RL
Clinical Cancer Research 10(8):2584-2586, 2004 *Published Date 4/15/2004*

- 99813 A phase II study of estramustine, docetaxel and Carboplatin with granulocyte-colony stimulating factor support in patients with hormone-refractory prostate cancer (CALGB 99813)
Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ
Cancer 98(12):2592-2598, 2003 *Published Date 12/15/2003*
- 99813 A phase II study of estramustine, docetaxel, carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer: CALGB 99813
Oh WK, Halabi S, Kelly WK, Godley PA, Werner C, Kantoff PW, Vogelzang NJ, Small EJ
Proc ASCO 21:779, 2002 *Published Date 5/1/2002*
- 99901 9-Nitrocarnitine as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer
Amin A, Halabi S, Werner CP, Small EJ, Stadler WM, Gelmann EP
Urologic Oncology 22(5):398-403, 2004 *Published Date 9/30/2004*
- 99908 Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium (E4897/C99908)
Dreicer R, Manola J, Roth B, See W, Kuross S, Edelman MJ, Hudes G, Wilding G
Cancer 100(8):1639-1645, 2004 *Published Date 4/15/2004*
- 119801 Telephone monitoring: early identification of psychological, physical and social distress in advanced stage cancer patients 65 or more years old
Kornblith AB, Dowell JM, Herndon JE, Rosenberg S, Engelman B, Small EJ, Morrison VA, Atkins JN, Muss HB, Holland JC
American Psychosocial Oncology Society, 2006 *Published Date 2/16/2006*
- 150105 Correlation of clinical response to imatinib mesylate (IM) and tumor genotype in patients treated with IM for metastatic GI stromal tumors (GISTs)
Heinrich MC, Shoemaker JS, Corless CL, Hollis DR, Demetri GD, Bertagnolli MM, Fletcher JA
Proc ASCO 23:7, 2005 *Published Date 5/16/2005*
- 309801 Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score
Grunbert SM, Srivastava A, Grunberg KJ, Weeks J
Support Care Cancer 10:624-629, 2002 *Published Date 8/2/2002*
- 360001 Improving accrual of older persons to cancer treatment trials: a randomized trial of the Cancer and Leukemia Group B comparing an educational intervention with standard information
Kimmick GG, Kornblith AB, Mandelblatt J, Peterson BL, Johnson JL, Wheeler JD, Heinze RV, Cohen HJ, Muss HB
Journal of Clinical Oncology 23(10):2201-2207, 2005 *Published Date 4/1/2005*
- 360001 A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001
Kimmick GG, Kornblith AB, Mandelblatt J, Peterson BL, Johnson JL, Wheeler JD, Cohen HJ, Muss HB
Proc ASCO:8040, 2004 *Published Date 5/1/2004*

- 509801 High dose interferon Alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
Kirkwood JM, Ibrahim J, Sosman JA, Sondak VK, Agarwala SS, Ernstoff M, Rao U
Journal of Clinical Oncology 19(9):2370-2380, 2001 *Published Date 4/1/2001*
- 509901 Phase II study of g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: CALGB 509901
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Zhang Z, Houghton AN, Haluska FG
Journal of Immunotherapy 29(1):95-101, 2006 *Published Date 1/1/2006*